viral meningitis: Viral infections of the leptomeninges and subarachnoid space. TOGAVIRIDAE INFECTIONS; FLAVIVIRIDAE INFECTIONS; RUBELLA; BUNYAVIRIDAE INFECTIONS; ORBIVIRUS infections; PICORNAVIRIDAE INFECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; RHABDOVIRIDAE INFECTIONS; ARENAVIRIDAE INFECTIONS; HERPESVIRIDAE INFECTIONS; ADENOVIRIDAE INFECTIONS; JC VIRUS infections; and RETROVIRIDAE INFECTIONS may cause this form of meningitis. Clinical manifestations include fever, headache, neck pain, vomiting, PHOTOPHOBIA, and signs of meningeal irritation. (From Joynt, Clinical Neurology, 1996, Ch26, pp1-3)
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
177 |
4. Check minimum number of eventsNone |
177 |
5. Include endpointsNone |
177 |
6. Filter based on genotype QC (FinnGen only) |
172 |
Control definitions (FinnGen only)
- Control exclude
- G6_NEUINFL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Meningitis, viral
based on the number of shared cases.
Similar with more cases:
- Meningitis
- Inflammatory diseases of the central nervous system
- Certain infectious and parasitic diseases
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1037 | 609 | 424 |
| Only index persons | 980 | 583 | 397 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 36.25 | 39.74 | 31.18 |
| Only index persons | 36.97 | 39.99 | 32.53 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 172 | 124 | 48 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.02 |
| Median age at first event (years) | 46.24 | 43.54 | 53.21 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 177
- Matched controls
- 1770
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G02.0*B00.3
ICD-10 Finland
Herpesviral meningitis
+∞
106.2
91
*
A87.9
ICD-10 Finland
Viral meningitis, unspecified
204.7
74.7
73
6
TAB00
NOMESCO Finland
Lumbar puncture
14.3
47.5
49
46
J05AB11
ATC
valaciclovir; oral
8.6
46.2
90
190
G02.0*B02.1
ICD-10 Finland
Zoster meningitis
+∞
33.4
31
*
G02.0*B01.0
ICD-10 Finland
Varicella meningitis
+∞
32.3
30
*
R51.80
ICD-10 Finland
Headache
6.0
30.9
84
232
G02.0*A87.0
ICD-10 Finland
Enteroviral meningitis
+∞
22.4
21
*
G02.0
ICD-10 Finland
Meningitis in viral diseases classified elsewhere
+∞
21.3
20
*
G03.9
ICD-10 Finland
Meningitis, unspecified
+∞
21.3
20
*
AA1AD
NOMESCO Finland
CT of head and brain
4.0
17.9
77
286
J05AB01
ATC
aciclovir; systemic
3.9
17.2
78
299
A86
ICD-10 Finland
Unspecified viral encephalitis
+∞
16.9
16
*
B00.3
ICD-10 Finland
Herpesviral meningitis
+∞
15.9
15
*
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
+∞
14.8
14
*
A87.8
ICD-10 Finland
Other viral meningitis
+∞
12.6
12
*
G05.1*B00.4
ICD-10 Finland
Herpesviral meningoencephalitis
+∞
11.6
11
*
N71
ICPC
Meningitis/encephalitis
+∞
11.6
11
*
5AB01, ,
NOMESCO Finland
+∞
10.5
10
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.1
10.2
55
225
H02AB06
ATC
prednisolone; systemic
2.5
8.5
100
599
N01
ICPC
Headache
3.0
8.2
43
171
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.6
8.1
30
96
R51
ICD-10 Finland
Headache
4.3
8.0
22
57
B02.9
ICD-10 Finland
Zoster without complication
4.2
7.5
21
55
R4110
NOMESCO Finland
Physiotherapy
2.5
7.4
60
298
G03.2
ICD-10 Finland
Benign recurrent meningitis [Mollaret]
+∞
7.3
7
*
B02.1
ICD-10 Finland
Zoster meningitis
+∞
7.3
7
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
7.2
89
533
XF400
NOMESCO Finland
ECG with 12 standard connections
3.1
7.2
34
127
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
8.1
7.1
15
20
B00.19
ICD-10 Finland
Other vesicular dermatitis caused by the herper simplex virus
23.6
6.7
9
*
ZX120
NOMESCO Finland
Intravenous
3.3
6.7
27
91
A87.0
ICD-10 Finland
Enteroviral meningitis
72.3
6.5
7
*
J45.9
ICD-10 Finland
Asthma, unspecified
2.6
6.4
45
207
N03AX16
ATC
[U] pregabalin
2.4
6.3
51
251
B00.4
ICD-10 Finland
Herpesviral encephalitis
+∞
6.3
6
*
XA800
NOMESCO Finland
Neuropsychological investigation
4.1
6.3
18
48
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
7.1e-01
5.1e-01
1.1e+00
1.2e+00
1.4e+00
6.8e-01
1.0e+50
cases:96.59%
controls:93.29%
cases:86.93%
controls:79.98%
cases:64.20%
controls:38.28%
cases:5.68%
controls:1.82%
cases:72.16%
controls:37.81%
cases:90.00%
controls:82.00%
cases:100.00%
controls:94.45%
170
1640
6
118
153
1406
23
352
113
673
63
1085
10
32
166
1726
127
664
49
1092
153
1403
17
308
149
1412
0
83
Neurology
13 [38004458]
13 [38004458]
1.2e+00
1.3e+00
3.4e+00
1.0e+50
4.4e+00
2.7e+00
1.6e+00
cases:21.02%
controls:7.62%
cases:11.36%
controls:3.47%
cases:11.93%
controls:0.46%
cases:60.80%
controls:0.00%
cases:25.57%
controls:0.40%
cases:34.12%
controls:3.39%
cases:30.20%
controls:8.23%
37
134
139
1624
20
61
156
1697
21
8
155
1750
107
0
69
1758
45
7
131
1749
58
58
112
1653
45
123
104
1372
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
3.5e-01
2.9e-01
2.0e+00
4.4e+00
2.4e+00
6.5e-01
2.6e-01
cases:26.70%
controls:20.36%
cases:19.89%
controls:15.64%
cases:21.02%
controls:3.41%
cases:25.57%
controls:0.40%
cases:26.70%
controls:3.19%
cases:27.06%
controls:16.19%
cases:34.90%
controls:29.16%
47
358
129
1400
35
275
141
1483
37
60
139
1698
45
7
131
1751
47
56
129
1700
46
277
124
1434
52
436
97
1059
Emergency Room Visit
ER [9203]
ER [9203]
6.4e-01
8.1e-01
3.3e+00
—
2.3e+00
1.1e+00
8.2e-01
cases:44.32%
controls:29.64%
cases:18.75%
controls:9.27%
cases:29.55%
controls:1.48%
—
—
cases:11.93%
controls:1.31%
cases:24.71%
controls:9.94%
cases:49.66%
controls:30.23%
78
521
98
1237
33
163
143
1595
52
26
124
1732
—
21
23
155
1733
42
170
128
1541
74
452
75
1043
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
1.6e-01
1.4e-01
1.7e+00
4.8e+00
2.2e+00
4.3e-01
1.8e-01
cases:35.23%
controls:31.63%
cases:28.98%
controls:26.22%
cases:26.70%
controls:5.97%
cases:31.82%
controls:0.40%
cases:35.23%
controls:5.52%
cases:34.12%
controls:25.19%
cases:47.65%
controls:43.14%
62
556
114
1202
51
461
125
1297
47
105
129
1653
56
7
120
1751
62
97
114
1659
58
431
112
1280
71
645
78
850
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
1.5e-01
1.4e-01
1.7e+00
4.8e+00
2.2e+00
4.5e-01
1.7e-01
cases:35.23%
controls:31.85%
cases:28.98%
controls:26.22%
cases:26.70%
controls:6.09%
cases:32.39%
controls:0.40%
cases:35.23%
controls:5.58%
cases:34.71%
controls:25.37%
cases:47.65%
controls:43.41%
62
560
114
1198
51
461
125
1297
47
107
129
1651
57
7
119
1751
62
98
114
1658
59
434
111
1277
71
649
78
846
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
1.3e-01
1.5e-01
1.7e+00
4.8e+00
2.2e+00
4.6e-01
1.8e-01
cases:34.66%
controls:31.74%
cases:28.98%
controls:26.00%
cases:26.70%
controls:6.09%
cases:31.82%
controls:0.40%
cases:35.23%
controls:5.47%
cases:34.71%
controls:25.19%
cases:47.65%
controls:43.21%
61
558
115
1200
51
457
125
1301
47
107
129
1651
56
7
120
1751
62
96
114
1660
59
431
111
1280
71
646
78
849
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
1.6e-01
1.4e-01
1.7e+00
4.8e+00
2.2e+00
4.5e-01
1.7e-01
cases:35.23%
controls:31.74%
cases:28.98%
controls:26.17%
cases:26.70%
controls:6.09%
cases:31.82%
controls:0.40%
cases:35.23%
controls:5.52%
cases:34.71%
controls:25.25%
cases:47.65%
controls:43.34%
62
558
114
1200
51
460
125
1298
47
107
129
1651
56
7
120
1751
62
97
114
1659
59
432
111
1279
71
648
78
847
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
1.3e-01
1.4e-01
1.7e+00
4.8e+00
2.2e+00
4.5e-01
1.7e-01
cases:34.66%
controls:31.74%
cases:28.98%
controls:26.22%
cases:26.70%
controls:6.09%
cases:31.82%
controls:0.40%
cases:35.23%
controls:5.58%
cases:34.71%
controls:25.31%
cases:47.65%
controls:43.41%
61
558
115
1200
51
461
125
1297
47
107
129
1651
56
7
120
1751
62
98
114
1658
59
433
111
1278
71
649
78
846
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
1.6e-01
1.4e-01
1.7e+00
4.8e+00
2.2e+00
4.5e-01
1.7e-01
cases:35.23%
controls:31.74%
cases:28.98%
controls:26.22%
cases:26.70%
controls:6.09%
cases:31.82%
controls:0.40%
cases:35.23%
controls:5.58%
cases:34.71%
controls:25.31%
cases:47.65%
controls:43.34%
62
558
114
1200
51
461
125
1297
47
107
129
1651
56
7
120
1751
62
98
114
1658
59
433
111
1278
71
648
78
847
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
1.5e-01
1.6e-01
1.7e+00
4.8e+00
2.2e+00
4.2e-01
1.7e-01
cases:35.23%
controls:31.97%
cases:29.55%
controls:26.34%
cases:26.70%
controls:6.14%
cases:32.39%
controls:0.40%
cases:35.23%
controls:5.69%
cases:34.12%
controls:25.37%
cases:47.65%
controls:43.34%
62
562
114
1196
52
463
124
1295
47
108
129
1650
57
7
119
1751
62
100
114
1656
58
434
112
1277
71
648
78
847
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
2.1e-01
2.5e-01
1.8e+00
4.5e+00
2.3e+00
4.8e-01
3.3e-01
cases:27.27%
controls:23.27%
cases:22.73%
controls:18.66%
cases:21.02%
controls:4.04%
cases:23.30%
controls:0.34%
cases:26.14%
controls:3.53%
cases:25.88%
controls:17.71%
cases:40.27%
controls:32.58%
48
409
128
1349
40
328
136
1430
37
71
139
1687
41
6
135
1752
46
62
130
1694
44
303
126
1408
60
487
89
1008
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
1.0e+00
1.5e+00
—
—
—
3.5e+00
3.0e+00
cases:5.68%
controls:2.16%
cases:5.11%
controls:1.19%
—
—
—
—
—
—
cases:21.76%
controls:0.82%
cases:26.85%
controls:1.87%
10
38
166
1720
9
21
167
1737
—
—
—
37
14
133
1697
40
28
109
1467
Infectious Disease
44 [38004484]
44 [38004484]
1.3e+00
1.9e+00
—
1.0e+50
—
3.5e+00
2.4e+00
cases:4.55%
controls:1.31%
cases:3.98%
controls:0.63%
—
—
cases:12.50%
controls:0.00%
—
—
cases:14.71%
controls:0.53%
cases:18.79%
controls:2.14%
8
23
168
1735
7
11
169
1747
—
22
0
154
1758
—
25
9
145
1702
28
32
121
1463
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
1.2e-01
1.2e-01
1.4e+00
4.5e+00
1.7e+00
2.6e-01
8.5e-02
cases:39.20%
controls:36.46%
cases:35.80%
controls:33.05%
cases:31.82%
controls:10.24%
cases:36.93%
controls:0.63%
cases:37.50%
controls:10.14%
cases:41.18%
controls:35.01%
cases:51.68%
controls:49.57%
69
641
107
1117
63
581
113
1177
56
180
120
1578
65
11
111
1747
66
178
110
1578
70
599
100
1112
77
741
72
754
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
3.0e-01
2.6e-01
3.1e+00
1.0e+50
2.9e+00
1.2e+00
5.2e-01
cases:12.50%
controls:9.61%
cases:5.68%
controls:4.44%
cases:9.66%
controls:0.46%
cases:9.09%
controls:0.00%
cases:7.39%
controls:0.46%
cases:12.94%
controls:4.32%
cases:17.45%
controls:11.17%
22
169
154
1589
10
78
166
1680
17
8
159
1750
16
0
160
1758
13
8
163
1748
22
74
148
1637
26
167
123
1328
Outpatient Visit
OP [9202]
OP [9202]
6.4e-01
4.5e-01
1.7e-01
3.8e+00
1.3e+00
8.5e-01
2.3e-01
cases:78.41%
controls:65.76%
cases:54.55%
controls:43.40%
cases:11.93%
controls:10.30%
cases:15.34%
controls:0.40%
cases:27.84%
controls:9.74%
cases:65.29%
controls:44.65%
cases:79.19%
controls:75.12%
138
1156
38
602
96
763
80
995
21
181
155
1577
27
7
149
1751
49
171
127
1585
111
764
59
947
118
1123
31
372
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
4.5e-01
6.6e-01
1.7e+00
—
2.7e+00
1.2e+00
8.9e-01
cases:11.93%
controls:7.96%
cases:9.09%
controls:4.89%
cases:6.25%
controls:1.19%
—
—
cases:11.36%
controls:0.85%
cases:12.94%
controls:4.27%
cases:22.15%
controls:10.43%
21
140
155
1618
16
86
160
1672
11
21
165
1737
—
20
15
156
1741
22
73
148
1638
33
156
116
1339
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
4.5e-01
6.5e-01
1.7e+00
—
2.7e+00
1.2e+00
8.8e-01
cases:11.93%
controls:7.96%
cases:9.09%
controls:4.95%
cases:6.25%
controls:1.19%
—
—
cases:11.36%
controls:0.85%
cases:12.94%
controls:4.32%
cases:22.15%
controls:10.57%
21
140
155
1618
16
87
160
1671
11
21
165
1737
—
20
15
156
1741
22
74
148
1637
33
158
116
1337
Emergency Medicine
93 [38004510]
93 [38004510]
4.7e-01
6.4e-01
3.1e+00
—
1.9e+00
1.4e+00
4.5e-01
cases:15.34%
controls:10.18%
cases:9.66%
controls:5.35%
cases:17.61%
controls:0.91%
—
—
cases:5.11%
controls:0.80%
cases:18.82%
controls:5.67%
cases:23.49%
controls:16.32%
27
179
149
1579
17
94
159
1664
31
16
145
1742
—
9
14
167
1742
32
97
138
1614
35
244
114
1251
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
4.4e-01
6.4e-01
1.7e+00
—
2.6e+00
1.2e+00
9.0e-01
cases:11.93%
controls:8.02%
cases:9.09%
controls:5.01%
cases:6.25%
controls:1.25%
—
—
cases:11.36%
controls:0.97%
cases:12.94%
controls:4.32%
cases:22.15%
controls:10.37%
21
141
155
1617
16
88
160
1670
11
22
165
1736
—
20
17
156
1739
22
74
148
1637
33
155
116
1340
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
4.5e-01
6.2e-01
1.8e+00
—
2.6e+00
1.1e+00
8.3e-01
cases:12.50%
controls:8.36%
cases:9.09%
controls:5.12%
cases:6.82%
controls:1.25%
—
—
cases:11.36%
controls:0.97%
cases:12.94%
controls:4.50%
cases:22.15%
controls:11.04%
22
147
154
1611
16
90
160
1668
12
22
164
1736
—
20
17
156
1739
22
77
148
1634
33
165
116
1330
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
4.1e-01
6.3e-01
1.7e+00
—
2.6e+00
1.2e+00
8.3e-01
cases:11.93%
controls:8.25%
cases:9.09%
controls:5.06%
cases:6.82%
controls:1.31%
—
—
cases:10.80%
controls:0.91%
cases:12.94%
controls:4.38%
cases:21.48%
controls:10.64%
21
145
155
1613
16
89
160
1669
12
23
164
1735
—
19
16
157
1740
22
75
148
1636
32
159
117
1336
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
3.5e-01
5.1e-01
1.8e+00
—
2.6e+00
1.1e+00
7.8e-01
cases:12.50%
controls:9.16%
cases:9.09%
controls:5.69%
cases:6.82%
controls:1.25%
—
—
cases:11.36%
controls:0.91%
cases:14.71%
controls:5.32%
cases:22.82%
controls:11.97%
22
161
154
1597
16
100
160
1658
12
22
164
1736
—
20
16
156
1740
25
91
145
1620
34
179
115
1316
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
2.0e-01
5.0e-01
2.4e+00
—
2.9e+00
9.1e-01
4.5e-01
cases:28.98%
controls:24.97%
cases:23.86%
controls:15.93%
cases:25.00%
controls:3.01%
—
—
cases:35.80%
controls:2.96%
cases:29.41%
controls:14.38%
cases:42.28%
controls:31.84%
51
439
125
1319
42
280
134
1478
44
53
132
1705
—
63
52
113
1704
50
246
120
1465
63
476
86
1019
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
4.6e-01
4.6e-01
1.7e+00
—
2.6e+00
1.1e+00
8.0e-01
cases:13.07%
controls:8.65%
cases:8.52%
controls:5.57%
cases:6.25%
controls:1.25%
—
—
cases:10.80%
controls:0.91%
cases:14.12%
controls:5.14%
cases:22.82%
controls:11.71%
23
152
153
1606
15
98
161
1660
11
22
165
1736
—
19
16
157
1740
24
88
146
1623
34
175
115
1320
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
4.6e-01
4.6e-01
1.7e+00
—
2.6e+00
1.1e+00
8.0e-01
cases:13.07%
controls:8.65%
cases:8.52%
controls:5.57%
cases:6.25%
controls:1.25%
—
—
cases:10.80%
controls:0.91%
cases:14.12%
controls:5.20%
cases:22.82%
controls:11.71%
23
152
153
1606
15
98
161
1660
11
22
165
1736
—
19
16
157
1740
24
89
146
1622
34
175
115
1320
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-8.3e-01
-9.9e-01
—
—
—
3.1e+00
3.9e+00
cases:11.93%
controls:23.66%
cases:3.98%
controls:10.07%
—
—
—
—
—
—
cases:7.06%
controls:0.35%
cases:16.11%
controls:0.40%
21
416
155
1342
7
177
169
1581
—
—
—
12
6
158
1705
24
6
125
1489
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
2.4e-01
5.7e-01
2.8e+00
1.0e+50
2.0e+00
1.2e+00
6.0e-01
cases:18.18%
controls:14.90%
cases:11.36%
controls:6.77%
cases:11.36%
controls:0.74%
cases:6.82%
controls:0.00%
cases:7.39%
controls:1.08%
cases:18.82%
controls:6.31%
cases:26.17%
controls:16.25%
32
262
144
1496
20
119
156
1639
20
13
156
1745
12
0
164
1758
13
19
163
1737
32
108
138
1603
39
243
110
1252
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
4.9e-01
5.3e-01
1.7e+00
—
2.5e+00
1.1e+00
7.7e-01
cases:14.20%
controls:9.22%
cases:9.66%
controls:5.92%
cases:6.82%
controls:1.37%
—
—
cases:11.36%
controls:1.03%
cases:14.71%
controls:5.38%
cases:22.82%
controls:12.04%
25
162
151
1596
17
104
159
1654
12
24
164
1734
—
20
18
156
1738
25
92
145
1619
34
180
115
1315
Headache
R51.80 [2000503603]
R51.80 [2000503603]
1.5e+00
—
1.0e+50
1.0e+50
—
2.5e+00
2.0e+00
cases:7.95%
controls:1.88%
—
—
cases:11.93%
controls:0.00%
cases:7.95%
controls:0.00%
—
—
cases:8.82%
controls:0.76%
cases:14.09%
controls:2.27%
14
33
162
1725
—
21
0
155
1758
14
0
162
1758
—
15
13
155
1698
21
34
128
1461
Inpatient Hospital
21 [8717]
21 [8717]
4.4e-01
4.8e-01
2.9e+00
—
3.0e+00
5.3e-01
4.7e-01
cases:39.77%
controls:29.86%
cases:13.07%
controls:8.53%
cases:15.34%
controls:0.97%
—
—
cases:14.77%
controls:0.85%
cases:14.71%
controls:9.23%
cases:34.23%
controls:24.55%
70
525
106
1233
23
150
153
1608
27
17
149
1741
—
26
15
150
1741
25
158
145
1553
51
367
98
1128
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
5.3e-01
5.3e-01
2.1e+00
—
2.0e+00
1.6e+00
7.2e-01
cases:10.23%
controls:6.26%
cases:5.68%
controls:3.41%
cases:6.25%
controls:0.80%
—
—
cases:5.68%
controls:0.80%
cases:12.94%
controls:3.04%
cases:13.42%
controls:7.02%
18
110
158
1648
10
60
166
1698
11
14
165
1744
—
10
14
166
1742
22
52
148
1659
20
105
129
1390
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
1.9e-01
2.1e-01
2.2e+00
—
2.7e+00
6.9e-01
2.5e-01
cases:28.41%
controls:24.74%
cases:21.59%
controls:18.32%
cases:23.30%
controls:3.19%
—
—
cases:32.95%
controls:3.19%
cases:29.41%
controls:17.24%
cases:38.93%
controls:33.24%
50
435
126
1323
38
322
138
1436
41
56
135
1702
—
58
56
118
1700
50
295
120
1416
58
497
91
998
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
1.9e-01
2.1e-01
2.2e+00
—
2.7e+00
7.0e-01
2.3e-01
cases:28.41%
controls:24.63%
cases:21.59%
controls:18.26%
cases:23.30%
controls:3.24%
—
—
cases:32.95%
controls:3.19%
cases:29.41%
controls:17.18%
cases:38.26%
controls:32.91%
50
433
126
1325
38
321
138
1437
41
57
135
1701
—
58
56
118
1700
50
294
120
1417
57
492
92
1003
General Practice
1 [38004446]
1 [38004446]
1.5e-01
3.3e-01
1.9e+00
1.0e+50
2.8e+00
4.9e-01
7.9e-01
cases:11.36%
controls:9.95%
cases:5.68%
controls:4.15%
cases:4.55%
controls:0.68%
cases:3.41%
controls:0.00%
cases:9.66%
controls:0.63%
cases:7.06%
controls:4.44%
cases:21.48%
controls:11.04%
20
175
156
1583
10
73
166
1685
8
12
168
1746
6
0
170
1758
17
11
159
1745
12
76
158
1635
32
165
117
1330
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
3.8e-01
4.9e-01
2.7e+00
1.0e+50
1.5e+00
1.0e+00
4.9e-01
cases:20.45%
controls:14.96%
cases:10.23%
controls:6.54%
cases:9.66%
controls:0.74%
cases:3.98%
controls:0.00%
cases:5.68%
controls:1.31%
cases:17.06%
controls:6.72%
cases:24.83%
controls:16.79%
36
263
140
1495
18
115
158
1643
17
13
159
1745
7
0
169
1758
10
23
166
1733
29
115
141
1596
37
251
112
1244
Ophthalmology
18 [38004463]
18 [38004463]
-1.3e-01
-2.1e-01
2.0e+00
—
1.9e+00
1.2e+00
6.1e-01
cases:11.93%
controls:13.37%
cases:5.68%
controls:6.94%
cases:3.98%
controls:0.57%
—
—
cases:7.39%
controls:1.14%
cases:15.88%
controls:5.14%
cases:23.49%
controls:14.25%
21
235
155
1523
10
122
166
1636
7
10
169
1748
—
13
20
163
1736
27
88
143
1623
35
213
114
1282
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
4.2e-01
5.2e-01
1.4e+00
—
2.0e+00
9.9e-01
7.5e-01
cases:14.20%
controls:9.84%
cases:11.36%
controls:7.05%
cases:7.95%
controls:2.16%
—
—
cases:10.80%
controls:1.65%
cases:14.71%
controls:6.02%
cases:24.16%
controls:13.04%
25
173
151
1585
20
124
156
1634
14
38
162
1720
—
19
29
157
1727
25
103
145
1608
36
195
113
1300
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
5.7e-01
—
—
1.0e+50
2.5e+00
1.7e+00
8.6e-01
cases:6.25%
controls:3.64%
—
—
—
—
cases:20.45%
controls:0.00%
cases:3.41%
controls:0.28%
cases:10.59%
controls:2.22%
cases:15.44%
controls:7.16%
11
64
165
1694
—
—
36
0
140
1758
6
5
170
1751
18
38
152
1673
23
107
126
1388
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
—
—
—
—
1.0e+50
3.3e+00
1.7e+00
—
—
—
—
—
—
—
—
cases:3.41%
controls:0.00%
cases:7.06%
controls:0.29%
cases:5.37%
controls:1.00%
—
—
—
—
6
0
170
1756
12
5
158
1706
8
15
141
1480
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
5.2e-01
1.4e-01
1.5e+00
1.0e+50
2.3e+00
1.1e+00
6.5e-01
cases:12.50%
controls:7.79%
cases:5.11%
controls:4.49%
cases:5.11%
controls:1.14%
cases:3.98%
controls:0.00%
cases:7.95%
controls:0.85%
cases:12.35%
controls:4.38%
cases:16.78%
controls:9.57%
22
137
154
1621
9
79
167
1679
9
20
167
1738
7
0
169
1758
14
15
162
1741
21
75
149
1636
25
143
124
1352
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
5.3e-01
2.5e-01
1.6e+00
—
2.6e+00
1.3e+00
9.1e-01
cases:8.52%
controls:5.18%
cases:3.98%
controls:3.13%
cases:3.98%
controls:0.80%
—
—
cases:7.39%
controls:0.57%
cases:9.41%
controls:2.63%
cases:16.11%
controls:7.16%
15
91
161
1667
7
55
169
1703
7
14
169
1744
—
13
10
163
1746
16
45
154
1666
24
107
125
1388
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
3.2e-01
7.0e-01
2.3e+00
—
2.3e+00
5.5e-01
5.0e-01
cases:14.20%
controls:10.75%
cases:7.95%
controls:4.10%
cases:5.11%
controls:0.51%
—
—
cases:4.55%
controls:0.46%
cases:8.24%
controls:4.91%
cases:19.46%
controls:12.78%
25
189
151
1569
14
72
162
1686
9
9
167
1749
—
8
8
168
1748
14
84
156
1627
29
191
120
1304
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
7.9e-01
5.9e-01
3.0e+00
1.0e+50
—
1.6e+00
9.8e-01
cases:5.68%
controls:2.67%
cases:2.84%
controls:1.59%
cases:5.68%
controls:0.28%
cases:12.50%
controls:0.00%
—
—
cases:7.06%
controls:1.46%
cases:10.07%
controls:4.01%
10
47
166
1711
5
28
171
1730
10
5
166
1753
22
0
154
1758
—
12
25
158
1686
15
60
134
1435
Internal Medicine
11 [38004456]
11 [38004456]
4.7e-01
5.5e-01
3.1e+00
1.0e+50
1.5e+00
7.6e-01
6.1e-01
cases:26.14%
controls:18.15%
cases:11.36%
controls:6.88%
cases:20.45%
controls:1.19%
cases:20.45%
controls:0.00%
cases:6.25%
controls:1.54%
cases:14.71%
controls:7.48%
cases:27.52%
controls:17.12%
46
319
130
1439
20
121
156
1637
36
21
140
1737
36
0
140
1758
11
27
165
1729
25
128
145
1583
41
256
108
1239
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
7.1e-02
2.1e-01
1.9e+00
—
2.5e+00
4.6e-01
2.8e-01
cases:28.98%
controls:27.53%
cases:25.57%
controls:21.79%
cases:23.86%
controls:4.44%
—
—
cases:34.09%
controls:4.21%
cases:29.41%
controls:20.75%
cases:42.95%
controls:36.19%
51
484
125
1274
45
383
131
1375
42
78
134
1680
—
60
74
116
1682
50
355
120
1356
64
541
85
954
Inpatient Visit
IP [9201]
IP [9201]
5.2e-02
5.6e-01
—
1.0e+50
2.8e+00
1.6e+00
2.8e-01
cases:4.55%
controls:4.32%
cases:2.84%
controls:1.65%
—
—
cases:2.84%
controls:0.00%
cases:5.11%
controls:0.34%
cases:5.29%
controls:1.11%
cases:7.38%
controls:5.69%
8
76
168
1682
5
29
171
1729
—
5
0
171
1758
9
6
167
1750
9
19
161
1692
11
85
138
1410
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
2.1e-01
9.9e-02
1.9e+00
—
2.5e+00
4.7e-01
1.8e-01
cases:31.82%
controls:27.53%
cases:20.45%
controls:18.89%
cases:17.05%
controls:3.13%
—
—
cases:26.14%
controls:2.96%
cases:23.53%
controls:16.13%
cases:39.60%
controls:35.38%
56
484
120
1274
36
332
140
1426
30
55
146
1703
—
46
52
130
1704
40
276
130
1435
59
529
90
966
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
-5.7e-02
1.2e-01
1.0e+00
3.2e+00
5.7e-01
7.2e-02
1.1e-01
cases:53.41%
controls:54.84%
cases:50.57%
controls:47.61%
cases:40.34%
controls:19.80%
cases:25.00%
controls:1.31%
cases:31.25%
controls:20.39%
cases:53.53%
controls:51.72%
cases:69.13%
controls:66.62%
94
964
82
794
89
837
87
921
71
348
105
1410
44
23
132
1735
55
358
121
1398
91
885
79
826
103
996
46
499
doxycycline; oral, parenteral
J01AA02 [21602800]
J01AA02 [21602800]
6.4e-01
1.1e+00
1.8e+00
—
1.7e+00
7.2e-01
7.3e-01
cases:28.98%
controls:17.75%
cases:13.64%
controls:5.23%
cases:3.98%
controls:0.68%
—
—
cases:2.84%
controls:0.51%
cases:10.59%
controls:5.44%
cases:26.85%
controls:15.05%
51
312
125
1446
24
92
152
1666
7
12
169
1746
—
5
9
171
1747
18
93
152
1618
40
225
109
1270
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
2.9e-01
3.3e-01
1.3e+00
—
2.0e+00
9.1e-01
5.6e-01
cases:18.75%
controls:14.68%
cases:12.50%
controls:9.27%
cases:7.39%
controls:2.10%
—
—
cases:10.80%
controls:1.65%
cases:18.82%
controls:8.53%
cases:28.19%
controls:18.33%
33
258
143
1500
22
163
154
1595
13
37
163
1721
—
19
29
157
1727
32
146
138
1565
42
274
107
1221
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
-1.3e-01
2.0e-01
1.8e+00
—
2.3e+00
4.5e-01
3.0e-01
cases:17.61%
controls:19.57%
cases:17.61%
controls:14.85%
cases:16.48%
controls:3.13%
—
—
cases:22.73%
controls:2.96%
cases:21.76%
controls:15.08%
cases:34.23%
controls:27.83%
31
344
145
1414
31
261
145
1497
29
55
147
1703
—
40
52
136
1704
37
258
133
1453
51
416
98
1079
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
4.5e-01
6.3e-01
2.7e+00
1.0e+50
—
1.3e+00
6.8e-01
cases:9.09%
controls:5.97%
cases:5.11%
controls:2.79%
cases:3.98%
controls:0.28%
cases:4.55%
controls:0.00%
—
—
cases:8.24%
controls:2.40%
cases:12.08%
controls:6.49%
16
105
160
1653
9
49
167
1709
7
5
169
1753
8
0
168
1758
—
14
41
156
1670
18
97
131
1398
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
9.0e-02
3.6e-01
1.8e+00
—
2.2e+00
7.9e-01
4.9e-01
cases:8.52%
controls:7.85%
cases:7.95%
controls:5.69%
cases:6.82%
controls:1.25%
—
—
cases:10.80%
controls:1.31%
cases:11.18%
controls:5.38%
cases:16.11%
controls:10.57%
15
138
161
1620
14
100
162
1658
12
22
164
1736
—
19
23
157
1733
19
92
151
1619
24
158
125
1337
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
1.1e+00
1.6e+00
—
—
—
1.5e+00
1.2e+00
cases:7.39%
controls:2.56%
cases:5.11%
controls:1.08%
—
—
—
—
—
—
cases:4.12%
controls:0.94%
cases:8.72%
controls:2.68%
13
45
163
1713
9
19
167
1739
—
—
—
7
16
163
1695
13
40
136
1455
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
1.1e+00
1.0e+00
—
—
—
1.0e+00
8.5e-01
cases:23.30%
controls:9.56%
cases:10.23%
controls:3.92%
—
—
—
—
—
—
cases:11.18%
controls:4.44%
cases:19.46%
controls:9.36%
41
168
135
1590
18
69
158
1689
—
—
—
19
76
151
1635
29
140
120
1355
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
1.1e+00
1.0e+00
—
—
—
1.0e+00
8.3e-01
cases:23.86%
controls:9.73%
cases:10.23%
controls:3.92%
—
—
—
—
—
—
cases:11.18%
controls:4.44%
cases:19.46%
controls:9.50%
42
171
134
1587
18
69
158
1689
—
—
—
19
76
151
1635
29
142
120
1353
Outpatient Hospital
22 [8756]
22 [8756]
4.1e-01
2.0e-02
1.9e+00
1.0e+50
2.0e+00
8.6e-01
4.9e-01
cases:31.82%
controls:23.61%
cases:5.68%
controls:5.57%
cases:3.98%
controls:0.63%
cases:14.77%
controls:0.00%
cases:3.41%
controls:0.46%
cases:11.76%
controls:5.32%
cases:23.49%
controls:15.85%
56
415
120
1343
10
98
166
1660
7
11
169
1747
26
0
150
1758
6
8
170
1748
20
91
150
1620
35
237
114
1258
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
3.4e-01
3.1e-01
1.5e+00
—
2.3e+00
6.2e-01
5.2e-01
cases:35.23%
controls:27.93%
cases:18.75%
controls:14.51%
cases:10.23%
controls:2.39%
—
—
cases:20.45%
controls:2.45%
cases:24.12%
controls:14.61%
cases:44.97%
controls:32.78%
62
491
114
1267
33
255
143
1503
18
42
158
1716
—
36
43
140
1713
41
250
129
1461
67
490
82
1005
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
2.6e-01
5.9e-01
—
—
2.4e+00
1.3e+00
6.0e-01
cases:7.95%
controls:6.26%
cases:5.68%
controls:3.24%
—
—
—
—
cases:6.82%
controls:0.63%
cases:8.82%
controls:2.69%
cases:14.09%
controls:8.23%
14
110
162
1648
10
57
166
1701
—
—
12
11
164
1745
15
46
155
1665
21
123
128
1372
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
2.3e-01
3.4e-01
1.4e+00
—
2.3e+00
4.1e-01
4.6e-01
cases:43.18%
controls:37.54%
cases:20.45%
controls:15.53%
cases:8.52%
controls:2.33%
—
—
cases:14.20%
controls:1.71%
cases:21.76%
controls:15.55%
cases:48.32%
controls:37.06%
76
660
100
1098
36
273
140
1485
15
41
161
1717
—
25
30
151
1726
37
266
133
1445
72
554
77
941
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
2.3e-01
3.4e-01
1.4e+00
—
2.3e+00
4.1e-01
4.6e-01
cases:43.18%
controls:37.54%
cases:20.45%
controls:15.53%
cases:8.52%
controls:2.33%
—
—
cases:14.20%
controls:1.71%
cases:21.76%
controls:15.55%
cases:48.32%
controls:37.06%
76
660
100
1098
36
273
140
1485
15
41
161
1717
—
25
30
151
1726
37
266
133
1445
72
554
77
941
aciclovir; oral, parenteral
J05AB01 [21603131]
J05AB01 [21603131]
6.6e-01
8.5e-01
—
—
—
2.1e+00
1.5e+00
cases:6.82%
controls:3.64%
cases:3.41%
controls:1.48%
—
—
—
—
—
—
cases:10.59%
controls:1.40%
cases:15.44%
controls:3.95%
12
64
164
1694
6
26
170
1732
—
—
—
18
24
152
1687
23
59
126
1436
Tension-type headache
G44.2 [45581495]
G44.2 [45581495]
1.1e+00
—
—
—
—
2.0e+00
1.3e+00
cases:3.41%
controls:1.19%
—
—
—
—
—
—
—
—
cases:4.71%
controls:0.64%
cases:7.38%
controls:2.07%
6
21
170
1737
—
—
—
—
8
11
162
1700
11
31
138
1464
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
26454-9 [3027475]
-1.0e+50
—
1.0e+50
1.0e+50
1.0e+50
—
3.3e+00
cases:0.00%
controls:0.34%
—
—
cases:7.39%
controls:0.00%
cases:17.05%
controls:0.00%
cases:5.68%
controls:0.00%
—
—
cases:8.05%
controls:0.33%
0
6
176
1752
—
13
0
163
1758
30
0
146
1758
10
0
166
1756
—
12
5
137
1490
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
8.6e-01
1.2e+00
—
—
—
1.9e+00
1.3e+00
cases:9.66%
controls:4.32%
cases:3.41%
controls:1.02%
—
—
—
—
—
—
cases:5.29%
controls:0.82%
cases:9.40%
controls:2.68%
17
76
159
1682
6
18
170
1740
—
—
—
9
14
161
1697
14
40
135
1455
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]
2880-3 [3019473]
-1.0e+50
—
1.0e+50
1.0e+50
1.0e+50
—
3.2e+00
cases:0.00%
controls:0.28%
—
—
cases:8.52%
controls:0.00%
cases:19.89%
controls:0.00%
cases:6.82%
controls:0.00%
—
—
cases:7.38%
controls:0.33%
0
5
176
1753
—
15
0
161
1758
35
0
141
1758
12
0
164
1756
—
11
5
138
1490
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 [3016543]
26465-5 [3016543]
-1.0e+50
—
1.0e+50
1.0e+50
1.0e+50
—
3.2e+00
cases:0.00%
controls:0.34%
—
—
cases:7.39%
controls:0.00%
cases:16.48%
controls:0.00%
cases:5.68%
controls:0.00%
—
—
cases:7.38%
controls:0.33%
0
6
176
1752
—
13
0
163
1758
29
0
147
1758
10
0
166
1756
—
11
5
138
1490
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
2.5e-01
1.4e-02
—
—
2.0e+00
1.2e+00
6.0e-01
cases:7.95%
controls:6.31%
cases:3.98%
controls:3.92%
—
—
—
—
cases:5.11%
controls:0.74%
cases:8.82%
controls:2.92%
cases:14.09%
controls:8.29%
14
111
162
1647
7
69
169
1689
—
—
9
13
167
1743
15
50
155
1661
21
124
128
1371
montelukast; oral
R03DC03 [21603356]
R03DC03 [21603356]
1.6e+00
1.2e+00
—
—
—
1.5e+00
1.5e+00
cases:8.52%
controls:1.82%
cases:3.41%
controls:1.08%
—
—
—
—
—
—
cases:4.71%
controls:1.05%
cases:7.38%
controls:1.74%
15
32
161
1726
6
19
170
1739
—
—
—
8
18
162
1693
11
26
138
1469
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
7.0e-02
—
—
1.0e+50
—
1.8e+00
1.3e+00
cases:3.41%
controls:3.19%
—
—
—
—
cases:2.84%
controls:0.00%
—
—
cases:4.12%
controls:0.70%
cases:10.74%
controls:3.14%
6
56
170
1702
—
—
5
0
171
1758
—
7
12
163
1699
16
47
133
1448
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
8.8e-02
4.1e-01
1.3e+00
—
1.7e+00
4.4e-01
1.7e-01
cases:27.84%
controls:26.11%
cases:26.14%
controls:19.06%
cases:12.50%
controls:3.64%
—
—
cases:18.75%
controls:3.93%
cases:25.88%
controls:18.35%
cases:40.27%
controls:36.19%
49
459
127
1299
46
335
130
1423
22
64
154
1694
—
33
69
143
1687
44
314
126
1397
60
541
89
954
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
2.9e-01
3.0e-01
1.3e+00
—
1.7e+00
1.3e+00
5.8e-01
cases:9.09%
controls:6.94%
cases:5.68%
controls:4.27%
cases:3.41%
controls:0.91%
—
—
cases:5.11%
controls:0.97%
cases:10.59%
controls:3.27%
cases:15.44%
controls:9.23%
16
122
160
1636
10
75
166
1683
6
16
170
1742
—
9
17
167
1739
18
56
152
1655
23
138
126
1357
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
5.7e-01
3.0e-01
1.9e+00
—
2.9e+00
7.5e-01
1.7e-01
cases:13.07%
controls:7.85%
cases:3.41%
controls:2.56%
cases:2.84%
controls:0.46%
—
—
cases:7.95%
controls:0.46%
cases:5.29%
controls:2.57%
cases:8.72%
controls:7.49%
23
138
153
1620
6
45
170
1713
5
8
171
1750
—
14
8
162
1748
9
44
161
1667
13
112
136
1383
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
8.6e-01
5.6e-01
—
1.0e+50
—
2.0e+00
8.2e-01
cases:11.93%
controls:5.40%
cases:2.84%
controls:1.65%
—
—
cases:6.82%
controls:0.00%
—
—
cases:9.41%
controls:1.34%
cases:12.75%
controls:6.02%
21
95
155
1663
5
29
171
1729
—
12
0
164
1758
—
16
23
154
1688
19
90
130
1405
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
5.9e-01
1.3e+00
—
—
—
1.5e+00
8.0e-01
cases:8.52%
controls:4.89%
cases:6.82%
controls:1.88%
—
—
—
—
—
—
cases:8.24%
controls:1.93%
cases:14.77%
controls:7.22%
15
86
161
1672
12
33
164
1725
—
—
—
14
33
156
1678
22
108
127
1387
Cell count panel - Cerebral spinal fluid
34563-7 [3044290]
34563-7 [3044290]
-1.0e+50
—
1.0e+50
1.0e+50
1.0e+50
—
2.8e+00
cases:0.00%
controls:0.34%
—
—
cases:7.39%
controls:0.00%
cases:18.75%
controls:0.00%
cases:5.11%
controls:0.00%
—
—
cases:6.04%
controls:0.40%
0
6
176
1752
—
13
0
163
1758
33
0
143
1758
9
0
167
1756
—
9
6
140
1489
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
47598-8 [3048816]
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.12%
controls:0.29%
—
—
—
—
—
—
—
7
5
163
1706
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
2.0e-01
3.5e-01
—
—
2.6e+00
4.3e-01
3.8e-01
cases:14.77%
controls:12.46%
cases:7.95%
controls:5.75%
—
—
—
—
cases:7.95%
controls:0.63%
cases:8.82%
controls:5.90%
cases:23.49%
controls:17.32%
26
219
150
1539
14
101
162
1657
—
—
14
11
162
1745
15
101
155
1610
35
259
114
1236
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
5.8e-01
6.7e-01
7.9e-01
—
1.9e+00
5.3e-01
6.7e-01
cases:22.73%
controls:14.16%
cases:11.36%
controls:6.14%
cases:2.84%
controls:1.31%
—
—
cases:10.23%
controls:1.71%
cases:11.76%
controls:7.31%
cases:26.17%
controls:15.32%
40
249
136
1509
20
108
156
1650
5
23
171
1735
—
18
30
158
1726
20
125
150
1586
39
229
110
1266
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
8.8e-01
—
—
—
—
—
2.5e+00
cases:2.84%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.33%
5
21
171
1737
—
—
—
—
—
6
5
143
1490
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
8.8e-01
—
—
—
—
—
2.5e+00
cases:2.84%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.33%
5
21
171
1737
—
—
—
—
—
6
5
143
1490
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
8.8e-01
—
—
—
—
—
2.5e+00
cases:2.84%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.33%
5
21
171
1737
—
—
—
—
—
6
5
143
1490
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
8.8e-01
—
—
—
—
—
2.5e+00
cases:2.84%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.33%
5
21
171
1737
—
—
—
—
—
6
5
143
1490
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
8.8e-01
—
—
—
—
—
2.5e+00
cases:2.84%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.33%
5
21
171
1737
—
—
—
—
—
6
5
143
1490
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
1.1e+00
—
—
—
—
—
2.5e+00
cases:3.98%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.40%
7
24
169
1734
—
—
—
—
—
7
6
142
1489
FEV1
20150-9 [3024653]
20150-9 [3024653]
1.1e+00
—
—
—
—
—
2.5e+00
cases:3.98%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.40%
7
24
169
1734
—
—
—
—
—
7
6
142
1489
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
1.1e+00
—
—
—
—
—
2.5e+00
cases:3.98%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.40%
7
24
169
1734
—
—
—
—
—
7
6
142
1489
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
8.4e-01
—
—
—
—
2.5e+00
—
cases:3.98%
controls:1.76%
—
—
—
—
—
—
—
—
cases:4.12%
controls:0.35%
—
—
7
31
169
1727
—
—
—
—
7
6
163
1705
—
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
3.9e-01
—
—
—
2.5e+00
1.2e+00
3.7e-01
cases:4.55%
controls:3.13%
—
—
—
—
—
—
cases:5.11%
controls:0.46%
cases:5.29%
controls:1.69%
cases:4.70%
controls:3.28%
8
55
168
1703
—
—
—
9
8
167
1748
9
29
161
1682
7
49
142
1446
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
5.4e-01
1.1e+00
—
—
1.9e+00
1.3e+00
1.1e+00
cases:13.07%
controls:8.02%
cases:5.11%
controls:1.76%
—
—
—
—
cases:2.84%
controls:0.46%
cases:7.06%
controls:1.93%
cases:16.11%
controls:6.29%
23
141
153
1617
9
31
167
1727
—
—
5
8
171
1748
12
33
158
1678
24
94
125
1401
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
3.1e-01
7.7e-01
1.6e+00
—
—
5.4e-01
3.1e-01
cases:34.66%
controls:27.93%
cases:18.18%
controls:9.33%
cases:5.68%
controls:1.19%
—
—
—
—
cases:12.94%
controls:8.01%
cases:33.56%
controls:27.02%
61
491
115
1267
32
164
144
1594
10
21
166
1737
—
—
22
137
148
1574
50
404
99
1091
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
—
—
—
1.0e+50
—
—
2.4e+00
—
—
—
—
—
—
cases:3.41%
controls:0.00%
—
—
—
—
cases:6.04%
controls:0.60%
—
—
—
6
0
170
1758
—
—
9
9
140
1486
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2472-9 [3028026]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.47%
—
—
—
—
—
—
7
7
142
1488
Venereal disease screening
171128005 [4064905]
171128005 [4064905]
—
—
—
—
—
-1.0e+50
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:4.03%
controls:0.40%
—
—
—
—
—
0
5
170
1706
6
6
143
1489
hydrocortisone
S01CB03 [21603666]
S01CB03 [21603666]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.36%
controls:0.33%
—
—
—
—
—
—
5
5
144
1490
hydrocortisone
S01BA02 [21603619]
S01BA02 [21603619]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.36%
controls:0.33%
—
—
—
—
—
—
5
5
144
1490
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
2.7e-01
2.4e-01
7.5e-01
—
2.3e+00
5.5e-01
5.2e-01
cases:18.18%
controls:14.56%
cases:10.23%
controls:8.19%
cases:2.84%
controls:1.37%
—
—
cases:7.95%
controls:0.85%
cases:11.76%
controls:7.13%
cases:27.52%
controls:18.46%
32
256
144
1502
18
144
158
1614
5
24
171
1734
—
14
15
162
1741
20
122
150
1589
41
276
108
1219
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
2.5e-01
3.5e-01
2.2e+00
1.0e+50
—
3.3e-01
7.0e-01
cases:5.68%
controls:4.49%
cases:3.98%
controls:2.84%
cases:4.55%
controls:0.51%
cases:2.84%
controls:0.00%
—
—
cases:3.53%
controls:2.57%
cases:8.72%
controls:4.55%
10
79
166
1679
7
50
169
1708
8
9
168
1749
5
0
171
1758
—
6
44
164
1667
13
68
136
1427
hepatitis A, inactivated, whole virus
J07BC02 [21601339]
J07BC02 [21601339]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.47%
—
—
—
—
—
—
6
7
143
1488
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
—
-1.0e+50
—
—
—
2.2e+00
7.5e-01
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:3.53%
controls:0.41%
cases:3.36%
controls:1.61%
—
0
9
176
1749
—
—
—
6
7
164
1704
5
24
144
1471
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.41%
—
—
—
—
—
—
—
6
7
164
1704
—
ciclesonide; inhalant
R03BA08 [21603291]
R03BA08 [21603291]
2.2e+00
—
—
—
—
-1.0e+50
—
cases:3.41%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
6
7
170
1751
—
—
—
—
0
9
170
1702
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
4.1e-01
5.7e-01
2.2e+00
1.0e+50
2.1e+00
8.5e-01
6.9e-01
cases:7.95%
controls:5.40%
cases:5.11%
controls:2.96%
cases:3.41%
controls:0.40%
cases:3.98%
controls:0.00%
cases:2.84%
controls:0.34%
cases:6.47%
controls:2.86%
cases:13.42%
controls:7.22%
14
95
162
1663
9
52
167
1706
6
7
170
1751
7
0
169
1758
5
6
171
1750
11
49
159
1662
20
108
129
1387
ciclesonide; nasal
R01AD13 [43534836]
R01AD13 [43534836]
2.2e+00
—
—
—
—
-1.0e+50
—
cases:3.41%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
6
7
170
1751
—
—
—
—
0
9
170
1702
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
6.8e-01
—
—
1.0e+50
—
2.2e+00
5.0e-01
cases:3.98%
controls:2.05%
—
—
—
—
cases:4.55%
controls:0.00%
—
—
cases:5.29%
controls:0.64%
cases:4.03%
controls:2.47%
7
36
169
1722
—
—
8
0
168
1758
—
9
11
161
1700
6
37
143
1458
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
14928-6 [3026989]
2.1e+00
—
-1.0e+50
—
—
—
8.0e-01
cases:6.82%
controls:0.85%
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:3.36%
controls:1.54%
12
15
164
1743
—
0
5
176
1753
—
—
—
5
23
144
1472
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
7.6e-01
8.8e-01
—
—
—
2.1e+00
9.6e-01
cases:6.25%
controls:3.01%
cases:2.84%
controls:1.19%
—
—
—
—
—
—
cases:6.47%
controls:0.82%
cases:9.40%
controls:3.81%
11
53
165
1705
5
21
171
1737
—
—
—
11
14
159
1697
14
57
135
1438
budesonide; inhalant
R03BA02 [21603285]
R03BA02 [21603285]
1.1e+00
7.2e-01
—
—
—
8.4e-01
1.0e+00
cases:12.50%
controls:4.66%
cases:6.25%
controls:3.13%
—
—
—
—
—
—
cases:5.88%
controls:2.63%
cases:12.08%
controls:4.68%
22
82
154
1676
11
55
165
1703
—
—
—
10
45
160
1666
18
70
131
1425
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
-2.3e-02
3.3e-01
2.1e+00
—
—
6.1e-01
3.9e-01
cases:8.52%
controls:8.70%
cases:6.82%
controls:5.01%
cases:6.82%
controls:0.91%
—
—
—
—
cases:11.18%
controls:6.37%
cases:24.83%
controls:18.33%
15
153
161
1605
12
88
164
1670
12
16
164
1742
—
—
19
109
151
1602
37
274
112
1221
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
6.8e-01
—
—
—
—
—
2.1e+00
cases:3.41%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
cases:6.04%
controls:0.80%
6
31
170
1727
—
—
—
—
—
9
12
140
1483
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
—
7.4e-01
—
1.0e+50
—
2.0e+00
8.7e-01
—
—
cases:4.55%
controls:2.22%
—
—
cases:9.09%
controls:0.00%
—
—
cases:8.24%
controls:1.17%
cases:10.74%
controls:4.82%
—
8
39
168
1719
—
16
0
160
1758
—
14
20
156
1691
16
72
133
1423
Fear sexually transm dis female
X23 [2002001308]
X23 [2002001308]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.04%
controls:0.87%
—
—
—
—
—
—
9
13
140
1482
Teaching
WZC30 [2001310891]
WZC30 [2001310891]
8.9e-01
—
—
—
—
2.0e+00
6.7e-01
cases:3.41%
controls:1.42%
—
—
—
—
—
—
—
—
cases:4.12%
controls:0.58%
cases:3.36%
controls:1.74%
6
25
170
1733
—
—
—
—
7
10
163
1701
5
26
144
1469
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
1.1e+00
1.2e+00
—
—
—
2.0e+00
7.9e-01
cases:6.82%
controls:2.33%
cases:3.41%
controls:1.08%
—
—
—
—
—
—
cases:5.29%
controls:0.76%
cases:7.38%
controls:3.48%
12
41
164
1717
6
19
170
1739
—
—
—
9
13
161
1698
11
52
138
1443
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
5.5e-01
5.5e-01
—
—
2.0e+00
7.8e-01
3.6e-01
cases:13.64%
controls:8.36%
cases:6.82%
controls:4.04%
—
—
—
—
cases:3.98%
controls:0.57%
cases:10.00%
controls:4.85%
cases:16.78%
controls:12.31%
24
147
152
1611
12
71
164
1687
—
—
7
10
169
1746
17
83
153
1628
25
184
124
1311
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.37%
controls:0.80%
—
—
—
—
—
—
8
12
141
1483
Dry eye syndrome
H04.10 [2000502254]
H04.10 [2000502254]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.05%
controls:1.27%
—
—
—
—
—
—
12
19
137
1476
Foot and toes X-ray examination
NH3AA [2001308267]
NH3AA [2001308267]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:0.74%
—
—
—
—
—
—
7
11
142
1484
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
4.7e-01
5.2e-01
—
1.0e+50
1.9e+00
8.4e-01
4.4e-01
cases:13.07%
controls:8.59%
cases:6.82%
controls:4.15%
—
—
cases:2.84%
controls:0.00%
cases:3.98%
controls:0.63%
cases:10.59%
controls:4.85%
cases:18.12%
controls:12.51%
23
151
153
1607
12
73
164
1685
—
5
0
171
1758
7
11
169
1745
18
83
152
1628
27
187
122
1308
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
4.9e-01
5.2e-01
—
1.0e+50
1.9e+00
8.2e-01
3.7e-01
cases:13.07%
controls:8.42%
cases:6.82%
controls:4.15%
—
—
cases:2.84%
controls:0.00%
cases:3.98%
controls:0.63%
cases:10.59%
controls:4.97%
cases:17.45%
controls:12.71%
23
148
153
1610
12
73
164
1685
—
5
0
171
1758
7
11
169
1745
18
85
152
1626
26
190
123
1305
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
3.7e-01
-6.1e-02
—
—
1.9e+00
9.8e-01
1.2e-01
cases:5.68%
controls:3.98%
cases:2.84%
controls:3.01%
—
—
—
—
cases:3.98%
controls:0.63%
cases:5.88%
controls:2.28%
cases:6.04%
controls:5.42%
10
70
166
1688
5
53
171
1705
—
—
7
11
169
1745
10
39
160
1672
9
81
140
1414
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
5.0e-01
—
—
—
—
1.8e+00
—
cases:3.41%
controls:2.10%
—
—
—
—
—
—
—
—
cases:4.12%
controls:0.70%
—
—
6
37
170
1721
—
—
—
—
7
12
163
1699
—
Otolaryngology
4 [38004449]
4 [38004449]
6.3e-01
4.7e-01
1.8e+00
—
1.4e+00
9.7e-01
6.4e-01
cases:14.77%
controls:8.48%
cases:5.68%
controls:3.64%
cases:3.98%
controls:0.68%
—
—
cases:2.84%
controls:0.68%
cases:9.41%
controls:3.80%
cases:17.45%
controls:10.03%
26
149
150
1609
10
64
166
1694
7
12
169
1746
—
5
12
171
1744
16
65
154
1646
26
150
123
1345
amoxicillin; oral, parenteral
J01CA04 [21602823]
J01CA04 [21602823]
2.0e-01
4.0e-01
1.9e+00
—
—
9.4e-01
7.8e-01
cases:27.27%
controls:23.49%
cases:10.23%
controls:7.11%
cases:2.84%
controls:0.46%
—
—
—
—
cases:12.94%
controls:5.49%
cases:34.23%
controls:19.26%
48
413
128
1345
18
125
158
1633
5
8
171
1750
—
—
22
94
148
1617
51
288
98
1207
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
5.5e-01
1.3e+00
—
—
—
1.7e+00
5.6e-01
cases:3.41%
controls:1.99%
cases:2.84%
controls:0.80%
—
—
—
—
—
—
cases:4.71%
controls:0.88%
cases:4.70%
controls:2.74%
6
35
170
1723
5
14
171
1744
—
—
—
8
15
162
1696
7
41
142
1454
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
A09 [45605189]
1.6e+00
-1.0e+50
—
—
—
—
9.0e-02
cases:6.82%
controls:1.42%
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
cases:3.36%
controls:3.08%
12
25
164
1733
0
11
176
1747
—
—
—
—
5
46
144
1449
Headache
N01 [2002000720]
N01 [2002000720]
—
—
1.0e+50
—
—
—
1.6e+00
—
—
—
—
cases:3.41%
controls:0.00%
—
—
—
—
—
—
cases:9.40%
controls:2.01%
—
—
6
0
170
1758
—
—
—
14
30
135
1465
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
4.3e-01
4.0e-01
—
—
—
1.6e+00
3.4e-01
cases:10.80%
controls:7.28%
cases:5.11%
controls:3.47%
—
—
—
—
—
—
cases:10.59%
controls:2.40%
cases:13.42%
controls:9.97%
19
128
157
1630
9
61
167
1697
—
—
—
18
41
152
1670
20
149
129
1346
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
3.8e-01
2.3e-01
—
—
2.1e+00
1.5e+00
6.2e-01
cases:9.09%
controls:6.43%
cases:2.84%
controls:2.28%
—
—
—
—
cases:2.84%
controls:0.34%
cases:8.24%
controls:1.87%
cases:10.74%
controls:6.09%
16
113
160
1645
5
40
171
1718
—
—
5
6
171
1750
14
32
156
1679
16
91
133
1404
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
M01AE03 [21603969]
4.9e-01
1.4e+00
—
—
—
1.5e+00
3.2e-01
cases:7.95%
controls:5.01%
cases:5.11%
controls:1.37%
—
—
—
—
—
—
cases:7.06%
controls:1.64%
cases:5.37%
controls:3.95%
14
88
162
1670
9
24
167
1734
—
—
—
12
28
158
1683
8
59
141
1436
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
-3.0e-01
5.3e-01
—
—
—
1.5e+00
6.0e-01
cases:3.98%
controls:5.29%
cases:4.55%
controls:2.73%
—
—
—
—
—
—
cases:8.82%
controls:2.10%
cases:12.08%
controls:7.02%
7
93
169
1665
8
48
168
1710
—
—
—
15
36
155
1675
18
105
131
1390
salmeterol and fluticasone
R03AK06 [21603280]
R03AK06 [21603280]
1.1e+00
1.5e+00
—
—
-1.0e+50
8.6e-01
7.5e-01
cases:5.11%
controls:1.82%
cases:5.11%
controls:1.19%
—
—
—
—
cases:0.00%
controls:0.51%
cases:3.53%
controls:1.52%
cases:4.70%
controls:2.27%
9
32
167
1726
9
21
167
1737
—
—
0
9
176
1747
6
26
164
1685
7
34
142
1461
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
1.1e-02
—
—
—
—
1.5e+00
2.8e-01
cases:5.11%
controls:5.06%
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.40%
cases:8.05%
controls:6.22%
9
89
167
1669
—
—
—
—
10
24
160
1687
12
93
137
1402
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
—
—
—
1.0e+50
—
—
1.5e+00
—
—
—
—
—
—
cases:3.41%
controls:0.00%
—
—
—
—
cases:10.07%
controls:2.54%
—
—
—
6
0
170
1758
—
—
15
38
134
1457
Diarrhoea
D11 [2002000310]
D11 [2002000310]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.71%
controls:1.74%
—
—
—
—
—
—
10
26
139
1469
Gastroenterology
10 [38004455]
10 [38004455]
4.3e-01
—
—
—
—
1.4e+00
6.7e-01
cases:5.68%
controls:3.75%
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.52%
cases:8.05%
controls:4.28%
10
66
166
1692
—
—
—
—
10
26
160
1685
12
64
137
1431
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
3.0e-01
—
—
-1.0e+50
1.7e+00
1.4e+00
8.5e-02
cases:6.82%
controls:5.12%
—
—
—
—
cases:0.00%
controls:0.34%
cases:3.98%
controls:0.74%
cases:8.82%
controls:2.34%
cases:7.38%
controls:6.82%
12
90
164
1668
—
—
0
6
176
1752
7
13
169
1743
15
40
155
1671
11
102
138
1393
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
LC2BE [2001306544]
3.3e-01
1.1e+00
—
—
—
1.4e+00
5.1e-01
cases:7.39%
controls:5.40%
cases:5.68%
controls:1.88%
—
—
—
—
—
—
cases:6.47%
controls:1.75%
cases:10.07%
controls:6.29%
13
95
163
1663
10
33
166
1725
—
—
—
11
30
159
1681
15
94
134
1401
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
4.6e-01
—
—
—
—
8.9e-01
1.3e+00
cases:7.39%
controls:4.78%
—
—
—
—
—
—
—
—
cases:2.94%
controls:1.23%
cases:9.40%
controls:2.68%
13
84
163
1674
—
—
—
—
5
21
165
1690
14
40
135
1455
candesartan; oral
C09CA06 [21601829]
C09CA06 [21601829]
7.5e-01
7.6e-01
—
—
1.2e+00
1.3e+00
5.7e-01
cases:7.39%
controls:3.64%
cases:6.82%
controls:3.30%
—
—
—
—
cases:2.84%
controls:0.85%
cases:11.18%
controls:3.33%
cases:10.07%
controls:5.95%
13
64
163
1694
12
58
164
1700
—
—
5
15
171
1741
19
57
151
1654
15
89
134
1406
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
8.2e-01
7.4e-01
—
—
1.9e+00
1.3e+00
5.7e-01
cases:6.25%
controls:2.84%
cases:4.55%
controls:2.22%
—
—
—
—
cases:2.84%
controls:0.46%
cases:7.06%
controls:2.05%
cases:8.72%
controls:5.15%
11
50
165
1708
8
39
168
1719
—
—
5
8
171
1748
12
35
158
1676
13
77
136
1418
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
4.0e-01
—
—
—
—
1.3e+00
1.6e-01
cases:6.25%
controls:4.27%
—
—
—
—
—
—
—
—
cases:7.06%
controls:2.10%
cases:6.04%
controls:5.22%
11
75
165
1683
—
—
—
—
12
36
158
1675
9
78
140
1417
roxithromycin; oral
J01FA06 [21602974]
J01FA06 [21602974]
1.2e+00
—
—
—
—
—
6.1e-01
cases:15.34%
controls:5.06%
—
—
—
—
—
—
—
—
—
—
cases:6.71%
controls:3.75%
27
89
149
1669
—
—
—
—
—
10
56
139
1439
Cardiology
6 [38004451]
6 [38004451]
6.8e-01
9.8e-01
—
—
-1.0e+50
1.2e+00
5.1e-01
cases:10.80%
controls:5.80%
cases:6.82%
controls:2.67%
—
—
—
—
cases:0.00%
controls:0.28%
cases:7.65%
controls:2.45%
cases:10.07%
controls:6.29%
19
102
157
1656
12
47
164
1711
—
—
0
5
176
1751
13
42
157
1669
15
94
134
1401
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.40%
controls:3.21%
—
—
—
—
—
—
14
48
135
1447
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
M01AC06 [21603965]
-2.7e-02
—
—
—
—
—
1.1e+00
cases:4.55%
controls:4.66%
—
—
—
—
—
—
—
—
—
—
cases:12.08%
controls:4.21%
8
82
168
1676
—
—
—
—
—
18
63
131
1432
ispaghula (psylla seeds); oral
A06AC01 [21600555]
A06AC01 [21600555]
3.9e-01
—
-1.0e+50
—
—
—
1.1e+00
cases:3.98%
controls:2.73%
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:8.72%
controls:3.01%
7
48
169
1710
—
0
8
176
1750
—
—
—
13
45
136
1450
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
6.6e-02
—
—
—
—
1.5e+00
1.1e+00
cases:4.55%
controls:4.27%
—
—
—
—
—
—
—
—
cases:4.71%
controls:1.11%
cases:8.72%
controls:3.01%
8
75
168
1683
—
—
—
—
8
19
162
1692
13
45
136
1450
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
-2.9e-01
—
2.3e+00
—
—
1.2e+00
1.1e+00
cases:2.84%
controls:3.75%
—
—
cases:2.84%
controls:0.28%
—
—
—
—
cases:4.12%
controls:1.29%
cases:10.74%
controls:3.95%
5
66
171
1692
—
5
5
171
1753
—
—
7
22
163
1689
16
59
133
1436
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
2.0e-01
7.3e-01
1.3e+00
1.0e+50
1.4e+00
1.0e+00
-3.4e-02
cases:11.93%
controls:10.01%
cases:10.80%
controls:5.52%
cases:2.84%
controls:0.80%
cases:5.68%
controls:0.00%
cases:5.11%
controls:1.25%
cases:11.18%
controls:4.44%
cases:12.08%
controls:12.44%
21
176
155
1582
19
97
157
1661
5
14
171
1744
10
0
166
1758
9
22
167
1734
19
76
151
1635
18
186
131
1309
Pain localized to other parts of lower abdomen
R10.3 [45534426]
R10.3 [45534426]
9.6e-01
1.0e+00
—
—
—
—
9.5e-01
cases:9.66%
controls:3.92%
cases:2.84%
controls:1.02%
—
—
—
—
—
—
—
—
cases:10.07%
controls:4.15%
17
69
159
1689
5
18
171
1740
—
—
—
—
15
62
134
1433
mirtazapine; oral
N06AX11 [21604740]
N06AX11 [21604740]
-1.0e-01
1.1e+00
—
—
—
1.1e+00
9.1e-01
cases:4.55%
controls:5.01%
cases:5.68%
controls:1.99%
—
—
—
—
—
—
cases:6.47%
controls:2.28%
cases:13.42%
controls:5.89%
8
88
168
1670
10
35
166
1723
—
—
—
11
39
159
1672
20
88
129
1407
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
9.1e-01
8.6e-01
—
1.0e+50
—
1.1e+00
6.5e-01
cases:10.80%
controls:4.66%
cases:5.11%
controls:2.22%
—
—
cases:4.55%
controls:0.00%
—
—
cases:6.47%
controls:2.16%
cases:11.41%
controls:6.29%
19
82
157
1676
9
39
167
1719
—
8
0
168
1758
—
11
37
159
1674
17
94
132
1401
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
8.9e-01
9.0e-01
—
—
—
7.5e-01
5.2e-01
cases:14.20%
controls:6.37%
cases:3.98%
controls:1.65%
—
—
—
—
—
—
cases:4.12%
controls:1.99%
cases:12.75%
controls:7.96%
25
112
151
1646
7
29
169
1729
—
—
—
7
34
163
1677
19
119
130
1376
mometasone; nasal
R01AD09 [21605051]
R01AD09 [21605051]
8.0e-01
-5.2e-02
-1.0e+50
—
—
4.5e-01
3.9e-01
cases:18.75%
controls:9.39%
cases:3.41%
controls:3.58%
cases:0.00%
controls:0.46%
—
—
—
—
cases:5.29%
controls:3.45%
cases:12.75%
controls:9.03%
33
165
143
1593
6
63
170
1695
0
8
176
1750
—
—
9
59
161
1652
19
135
130
1360
salbutamol; inhalant
R03AC02 [21603256]
R03AC02 [21603256]
7.7e-01
7.7e-01
—
—
—
4.5e-01
6.4e-01
cases:25.00%
controls:13.37%
cases:13.64%
controls:6.83%
—
—
—
—
—
—
cases:9.41%
controls:6.20%
cases:23.49%
controls:13.98%
44
235
132
1523
24
120
152
1638
—
—
—
16
106
154
1605
35
209
114
1286
Orthopedic Surgery
20 [38004465]
20 [38004465]
2.1e-01
3.9e-01
—
—
—
1.8e-01
7.6e-01
cases:13.64%
controls:11.38%
cases:6.25%
controls:4.32%
—
—
—
—
—
—
cases:5.88%
controls:4.97%
cases:21.48%
controls:11.37%
24
200
152
1558
11
76
165
1682
—
—
—
10
85
160
1626
32
170
117
1325
Anxiety disorder/anxiety state
P74 [2002000868]
P74 [2002000868]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
6
176
1752
—
—
—
—
—
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
9.0e-01
1.3e+00
—
—
—
1.2e+00
6.6e-01
cases:3.98%
controls:1.65%
cases:2.84%
controls:0.80%
—
—
—
—
—
—
cases:4.12%
controls:1.29%
cases:4.70%
controls:2.47%
7
29
169
1729
5
14
171
1744
—
—
—
7
22
163
1689
7
37
142
1458
External hemorrhoids without complication
I84.5 [45581832]
I84.5 [45581832]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
—
Antenatal screening for malformation
717800004 [36713462]
717800004 [36713462]
2.3e-01
—
—
—
—
8.0e-01
3.0e-02
cases:5.68%
controls:4.55%
—
—
—
—
—
—
—
—
cases:2.94%
controls:1.34%
cases:5.37%
controls:5.22%
10
80
166
1678
—
—
—
—
5
23
165
1688
8
78
141
1417
Intraoral radiographic dental examination
EB1AA [2001301903]
EB1AA [2001301903]
1.8e-01
1.3e-01
—
—
—
6.2e-01
5.3e-01
cases:14.20%
controls:12.12%
cases:5.68%
controls:5.01%
—
—
—
—
—
—
cases:7.65%
controls:4.27%
cases:20.13%
controls:12.91%
25
213
151
1545
10
88
166
1670
—
—
—
13
73
157
1638
30
193
119
1302
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent
O24.0 [45558213]
O24.0 [45558213]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.74%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
13
176
1745
0
7
176
1751
—
—
—
—
0
11
149
1484
Extensive angiography of hear and/or coronary arteries
FN1BC [2001303000]
FN1BC [2001303000]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
—
Unwanted pregnancy
W79 [2002001270]
W79 [2002001270]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
Mucopurulent conjunctivitis
H10.0 [45596007]
H10.0 [45596007]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
0
8
170
1703
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
8.8e-01
—
—
1.0e+50
—
—
1.4e+00
cases:2.84%
controls:1.19%
—
—
—
—
cases:2.84%
controls:0.00%
—
—
—
—
cases:6.04%
controls:1.54%
5
21
171
1737
—
—
5
0
171
1758
—
—
9
23
140
1472
More than three and less than five hours
ZXE20 [2001311408]
ZXE20 [2001311408]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
176
1740
—
—
—
—
—
—
Urine symptom/complaint other
U07 [2002001142]
U07 [2002001142]
-1.0e+50
-1.0e+50
—
—
—
—
1.5e+00
cases:0.00%
controls:0.74%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:3.36%
controls:0.80%
0
13
176
1745
0
5
176
1753
—
—
—
—
5
12
144
1483
Laparoscopy
JAH01 [2001304475]
JAH01 [2001304475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
176
1752
—
—
—
—
—
—
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
1.3e-01
—
-1.0e+50
—
-1.0e+50
6.9e-01
4.8e-01
cases:7.39%
controls:6.54%
—
—
cases:0.00%
controls:0.28%
—
—
cases:0.00%
controls:0.40%
cases:4.12%
controls:2.10%
cases:12.75%
controls:8.29%
13
115
163
1643
—
0
5
176
1753
—
0
7
176
1749
7
36
163
1675
19
124
130
1371
Dental calculus supragingival
K03.64 [2000502689]
K03.64 [2000502689]
-8.0e-02
—
—
—
—
—
9.0e-01
cases:5.11%
controls:5.52%
—
—
—
—
—
—
—
—
—
—
cases:12.75%
controls:5.62%
9
97
167
1661
—
—
—
—
—
19
84
130
1411
betamethasone
S02BA07 [21605169]
S02BA07 [21605169]
3.2e-01
—
-1.0e+50
—
-1.0e+50
—
4.0e-01
cases:7.95%
controls:5.92%
—
—
cases:0.00%
controls:0.34%
—
—
cases:0.00%
controls:0.28%
—
—
cases:8.72%
controls:6.02%
14
104
162
1654
—
0
6
176
1752
—
0
5
176
1751
—
13
90
136
1405
Other and unspecified abdominal pain
R10.4 [45568113]
R10.4 [45568113]
1.1e-01
—
—
—
—
6.8e-01
3.6e-01
cases:5.68%
controls:5.12%
—
—
—
—
—
—
—
—
cases:3.53%
controls:1.81%
cases:10.07%
controls:7.22%
10
90
166
1668
—
—
—
—
6
31
164
1680
15
108
134
1387
Very extensive MRI examination of brain with high intensity magnet
AA1DG [2001300120]
AA1DG [2001300120]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:3.98%
controls:0.00%
—
—
—
—
—
—
—
—
—
7
0
169
1758
—
—
—
ketoprofen; ointment
M02AA10 [21604046]
M02AA10 [21604046]
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.88%
—
—
—
—
—
—
—
5
15
165
1696
—
Examination of eyes and vision
Z01.0 [45566391]
Z01.0 [45566391]
2.0e-01
—
—
—
—
1.5e+00
5.1e-01
cases:2.84%
controls:2.33%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.70%
cases:4.70%
controls:2.88%
5
41
171
1717
—
—
—
—
5
12
165
1699
7
43
142
1452
methylprednisolone aceponate
D07AC14 [21602133]
D07AC14 [21602133]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
2.3e-01
—
—
—
—
—
8.7e-01
cases:4.55%
controls:3.64%
—
—
—
—
—
—
—
—
—
—
cases:6.04%
controls:2.61%
8
64
168
1694
—
—
—
—
—
9
39
140
1456
Preventive oral care by dental hygienist
SCF02 [2001310319]
SCF02 [2001310319]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
176
1751
—
—
—
—
—
—
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
NGD05 [2001308109]
2.1e+00
—
—
—
—
-1.0e+50
—
cases:2.84%
controls:0.34%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
5
6
171
1752
—
—
—
—
0
5
170
1706
—
etoricoxib; oral
M01AH05 [21603996]
M01AH05 [21603996]
4.0e-01
-1.7e-01
—
—
—
-7.1e-01
4.2e-01
cases:15.91%
controls:11.26%
cases:4.55%
controls:5.35%
—
—
—
—
—
—
cases:2.94%
controls:5.79%
cases:19.46%
controls:13.65%
28
198
148
1560
8
94
168
1664
—
—
—
5
99
165
1612
29
204
120
1291
Anxiety disorder, unspecified
F41.9 [45542849]
F41.9 [45542849]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
9
170
1702
—
Diabetes mellitus screening
171183004 [4064918]
171183004 [4064918]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
8
149
1487
Phlebitis and thrombophlebitis of other sites
I80.8 [45601087]
I80.8 [45601087]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
Lumbago with sciatica
M54.4 [45553205]
M54.4 [45553205]
5.9e-01
-1.0e+50
—
—
—
—
—
cases:2.84%
controls:1.59%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
5
28
171
1730
0
7
176
1751
—
—
—
—
—
HLA-B27 [Presence]
4821-5 [3008898]
4821-5 [3008898]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
0
17
176
1741
0
6
176
1752
—
—
—
—
0
17
149
1478
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
Z03.9 [45552062]
—
—
—
—
—
—
6.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:2.47%
—
—
—
—
—
—
7
37
142
1458
Axillary plexus blockaced
WX204 [2001310780]
WX204 [2001310780]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
—
phenylephrine, combinations
R01BA53 [21603214]
R01BA53 [21603214]
7.3e-01
—
—
—
—
—
—
cases:6.82%
controls:3.41%
—
—
—
—
—
—
—
—
—
—
—
—
12
60
164
1698
—
—
—
—
—
—
antibiotics in combination with other drugs
S01AA20 [21603571]
S01AA20 [21603571]
-1.9e-01
—
—
—
—
6.0e-01
3.4e-01
cases:5.11%
controls:6.14%
—
—
—
—
—
—
—
—
cases:2.94%
controls:1.64%
cases:8.05%
controls:5.89%
9
108
167
1650
—
—
—
—
5
28
165
1683
12
88
137
1407
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
14683-7 [3009508]
1.9e-01
-5.2e-02
—
—
-1.0e+50
-9.2e-02
-2.0e-01
cases:6.82%
controls:5.69%
cases:3.41%
controls:3.58%
—
—
—
—
cases:0.00%
controls:0.57%
cases:2.94%
controls:3.21%
cases:6.04%
controls:7.29%
12
100
164
1658
6
63
170
1695
—
—
0
10
176
1746
5
55
165
1656
9
109
140
1386
Pregnancy, Medical examin/health eval partial
W31 [2002001224]
W31 [2002001224]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
—
palonosetron, combinations
A04AA55 [45893275]
A04AA55 [45893275]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
176
1750
—
—
—
—
—
—
clopidogrel; oral
B01AC04 [21600989]
B01AC04 [21600989]
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.76%
—
—
—
—
—
—
—
5
13
165
1698
—
Emergency use of U07.1 | COVID-19, virus identified
U07.1 [45756093]
U07.1 [45756093]
—
—
—
—
—
—
3.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.05%
controls:5.62%
—
—
—
—
—
—
12
84
137
1411
Glutamate decarboxylase 65 Ab [Units/volume] in Serum
13926-1 [3020148]
13926-1 [3020148]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
Open wound of scalp
S01.0 [45592468]
S01.0 [45592468]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
176
1746
—
—
—
—
—
—
Burn/scald
S14 [2002000979]
S14 [2002000979]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
6
176
1752
—
—
—
—
—
0
8
149
1487
Microscopic observation [Identifier] in Vaginal fluid by Gram stain
14361-0 [3000855]
14361-0 [3000855]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
16
176
1742
—
—
—
—
—
0
6
149
1489
General health counselling
SPAT1312 [2001700413]
SPAT1312 [2001700413]
-6.9e-02
—
—
—
—
—
-2.3e-02
cases:5.11%
controls:5.46%
—
—
—
—
—
—
—
—
—
—
cases:5.37%
controls:5.48%
9
96
167
1662
—
—
—
—
—
8
82
141
1413
timolol, combinations
S01ED51 [21603705]
S01ED51 [21603705]
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
0
22
176
1736
—
—
—
0
7
176
1749
—
—
Other contraceptive management
Z30.8 [45571338]
Z30.8 [45571338]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
5
176
1753
—
—
—
—
—
0
8
149
1487
Contusion of lower back and pelvis
S30.0 [45549279]
S30.0 [45549279]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
6
176
1752
—
—
—
—
—
Other diagnostic examination of periferal vessel
XPX99 [2001309755]
XPX99 [2001309755]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
176
1748
—
—
—
—
—
—
Ultrasound examination of mammary glands
HA1AE [2001303886]
HA1AE [2001303886]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
0
8
176
1750
—
—
—
—
—
Root filling of tooth with onetwo root canals
SGB20 [2001310389]
SGB20 [2001310389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
176
1750
—
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]
SMOKING-1-1-0 [2002330116]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
41
176
1717
—
—
—
—
—
—
pseudoephedrine; oral
R01BA02 [21603210]
R01BA02 [21603210]
5.8e-01
—
-1.0e+50
—
—
—
5.0e-01
cases:3.41%
controls:1.93%
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:4.03%
controls:2.47%
6
34
170
1724
—
0
5
176
1753
—
—
—
6
37
143
1458
Body temperature
8310-5 [3020891]
8310-5 [3020891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
176
1749
—
—
—
—
—
—
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
EB1SA [2001301918]
1.0e-02
-1.5e-01
-1.0e+50
—
—
-2.0e-01
6.8e-01
cases:11.36%
controls:11.26%
cases:2.84%
controls:3.30%
cases:0.00%
controls:0.28%
—
—
—
—
cases:3.53%
controls:4.27%
cases:22.15%
controls:12.64%
20
198
156
1560
5
58
171
1700
0
5
176
1753
—
—
6
73
164
1638
33
189
116
1306
itraconazole; oral, parenteral
J02AC02 [21603081]
J02AC02 [21603081]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
Supervision of other normal pregnancy
Z34.8 [45537628]
Z34.8 [45537628]
4.7e-01
—
—
—
—
—
—
cases:3.41%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
6
38
170
1720
—
—
—
—
—
—
Low pressure glaucoma
H40.11 [2000502333]
H40.11 [2000502333]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
—
Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid
22118-4 [3011166]
22118-4 [3011166]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:8.52%
controls:0.00%
—
—
—
—
—
—
—
—
—
15
0
161
1758
—
—
—
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
1.3e+00
—
—
—
—
1.4e+00
—
cases:3.41%
controls:0.91%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.76%
—
—
6
16
170
1742
—
—
—
—
5
13
165
1698
—
isotretinoin; oral
D10BA01 [21602320]
D10BA01 [21602320]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
17
176
1741
0
5
176
1753
—
—
—
—
—
Nephrology
39 [38004479]
39 [38004479]
1.4e+00
—
—
—
—
2.0e+00
—
cases:2.84%
controls:0.74%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.41%
—
—
5
13
171
1745
—
—
—
—
5
7
165
1704
—
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
49002-9 [3050449]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
12
149
1483
dexchlorpheniramine, combinations
R06AB52 [21603467]
R06AB52 [21603467]
1.0e+00
—
—
—
—
—
—
cases:2.84%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
171
1740
—
—
—
—
—
—
insulin aspart; parenteral
A10AB05 [21600719]
A10AB05 [21600719]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
0
11
176
1745
—
—
Surveillance of (intrauterine) contraceptive device
Z30.5 [45547300]
Z30.5 [45547300]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.67%
—
0
8
176
1750
—
—
—
—
0
25
149
1470
aripiprazole; oral, parenteral
N05AX12 [21604562]
N05AX12 [21604562]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:1.00%
—
0
11
176
1747
—
—
—
0
10
170
1701
0
15
149
1480
Throat symptom/complaint
R21 [2002000891]
R21 [2002000891]
6.0e-02
—
—
—
—
—
-7.6e-02
cases:3.98%
controls:3.75%
—
—
—
—
—
—
—
—
—
—
cases:3.36%
controls:3.61%
7
66
169
1692
—
—
—
—
—
5
54
144
1441
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
J01EC20 [21602948]
5.3e-01
-1.0e+50
—
—
—
—
—
cases:3.98%
controls:2.39%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
7
42
169
1716
0
7
176
1751
—
—
—
—
—
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
J07BA01 [21601331]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
0
24
176
1734
—
—
—
—
0
9
170
1702
—
Exploration of knee joint, arthroscopic
NGA30 [2001308091]
NGA30 [2001308091]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
7
149
1488
tibolone; oral
G03CX01 [21602536]
G03CX01 [21602536]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.47%
—
0
5
176
1753
—
—
—
0
5
170
1706
0
7
149
1488
Apolipoprotein B [Mass/volume] in Serum or Plasma
1884-6 [3014791]
1884-6 [3014791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
9
149
1486
Health examination of person liable for military service
SPAT1321 [2001700422]
SPAT1321 [2001700422]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
6
170
1705
—
Celiac disease serology panel - Serum
94494-2 [36660697]
94494-2 [36660697]
—
—
—
—
—
—
7.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:2.21%
—
—
—
—
—
—
7
33
142
1462
Simple adjuvant cytostatic therapy
WB103 [2001310627]
WB103 [2001310627]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
176
1751
—
—
—
—
—
—
General symptom/complaint other
A29 [2002000163]
A29 [2002000163]
—
-1.0e+50
—
—
—
—
8.6e-01
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:4.03%
controls:1.74%
—
0
9
176
1749
—
—
—
—
6
26
143
1469
Synovial cyst of popliteal space [Baker]
M71.2 [45596669]
M71.2 [45596669]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
8090/3-C44.3 [44499724]
8090/3-C44.3 [44499724]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
—
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
E11.7 [45561950]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
6
149
1489
Aortic (valve) insufficiency
I35.1 [45572087]
I35.1 [45572087]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
176
1750
—
—
—
—
—
—
Streptococcal pharyngitis
J02.0 [45533537]
J02.0 [45533537]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
5
176
1753
—
—
—
—
—
0
6
149
1489
Curettage of cervix and body of uterus
LCA13 [2001306553]
LCA13 [2001306553]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
176
1752
—
—
—
—
—
—
Person encountering health services in unspecified circumstances
Z76.9 [45609967]
Z76.9 [45609967]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
0
16
176
1742
—
—
—
—
0
6
170
1705
—
Dysthymia
F34.1 [45586238]
F34.1 [45586238]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
8
176
1750
—
—
—
—
—
0
5
149
1490
Guidance concerning rehabilitation services and livelihood
SPAT1221 [2001700322]
SPAT1221 [2001700322]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
176
1751
—
—
—
—
—
—
indapamide; oral
C03BA11 [21601499]
C03BA11 [21601499]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
6
149
1489
Breast lump/mass female
X19 [2002001304]
X19 [2002001304]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
—
Atrial fibrillation/flutter
K78 [2002000605]
K78 [2002000605]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
IgG subclass 1 [Mass/volume] in Serum
2466-1 [3027135]
2466-1 [3027135]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.00%
—
—
—
—
—
—
—
6
0
164
1711
—
Other somatoform disorders
F45.8 [45600750]
F45.8 [45600750]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
170
1706
—
Special examination, unspecified
Z01.9 [45576123]
Z01.9 [45576123]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
0
6
176
1752
—
—
—
—
—
0
7
149
1488
Depressive episode
F32 [45595904]
F32 [45595904]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
0
12
176
1746
—
—
—
—
0
5
170
1706
—
insulin lispro; parenteral
A10AB04 [21600718]
A10AB04 [21600718]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.79%
cases:0.00%
controls:2.28%
cases:0.00%
controls:0.51%
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:2.40%
cases:0.00%
controls:2.94%
0
49
176
1709
0
40
176
1718
0
9
176
1749
—
0
8
176
1748
0
41
170
1670
0
44
149
1451
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
MA2HE [2001306836]
5.2e-02
—
—
—
—
—
2.6e-01
cases:3.41%
controls:3.24%
—
—
—
—
—
—
—
—
—
—
cases:3.36%
controls:2.61%
6
57
170
1701
—
—
—
—
—
5
39
144
1456
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.70%
controls:1.74%
—
—
—
—
—
—
7
26
142
1469
Apolipoprotein B/Apolipoprotein A-I [Percentile]
9340-1 [3011831]
9340-1 [3011831]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
8
149
1487
oseltamivir; oral
J05AH02 [21603179]
J05AH02 [21603179]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
176
1747
—
—
—
—
—
—
Moderate depressive episode
F32.1 [45552478]
F32.1 [45552478]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
176
1745
—
—
—
—
—
—
Chronic periodontitis
K05.3 [45586694]
K05.3 [45586694]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
176
1751
—
—
—
—
—
—
One-surface restoration
SFA10 [2001310358]
SFA10 [2001310358]
9.6e-03
2.5e-01
-1.0e+50
—
—
-5.7e-01
4.3e-01
cases:11.93%
controls:11.83%
cases:5.68%
controls:4.49%
cases:0.00%
controls:0.51%
—
—
—
—
cases:2.94%
controls:5.08%
cases:20.13%
controls:14.11%
21
208
155
1550
10
79
166
1679
0
9
176
1749
—
—
5
87
165
1624
30
211
119
1284
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
5.9e-01
—
—
—
—
—
8.4e-01
cases:2.84%
controls:1.59%
—
—
—
—
—
—
—
—
—
—
cases:3.36%
controls:1.47%
5
28
171
1730
—
—
—
—
—
5
22
144
1473
Chronic atrial fibrillation
I48.2 [45591467]
I48.2 [45591467]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
Monitoring of normal pregnancy
SPAT1196 [2001700297]
SPAT1196 [2001700297]
7.4e-01
—
—
—
—
-1.0e+50
—
cases:3.41%
controls:1.65%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
6
29
170
1729
—
—
—
—
0
6
170
1705
—
Gradual caries removal, at least two tooth surfaces
SFD11 [2001310373]
SFD11 [2001310373]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
6
149
1489
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
WYA05 [2001310871]
1.8e-01
5.0e-01
—
—
—
—
6.0e-01
cases:10.23%
controls:8.70%
cases:3.98%
controls:2.45%
—
—
—
—
—
—
—
—
cases:11.41%
controls:6.62%
18
153
158
1605
7
43
169
1715
—
—
—
—
17
99
132
1396
More than five and less than seven hours
ZXE30 [2001311411]
ZXE30 [2001311411]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
176
1752
—
—
—
—
—
—
Shoulder lesion, unspecified
M75.9 [45557986]
M75.9 [45557986]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
176
1751
—
—
—
—
—
—
erdosteine; oral
R05CB15 [21603394]
R05CB15 [21603394]
1.1e+00
—
—
—
—
—
1.2e+00
cases:5.11%
controls:1.71%
—
—
—
—
—
—
—
—
—
—
cases:6.71%
controls:2.14%
9
30
167
1728
—
—
—
—
—
10
32
139
1463
European tick borne encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay
69924-9 [42868415]
69924-9 [42868415]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:3.41%
controls:0.00%
—
—
—
—
—
—
—
—
—
6
0
170
1758
—
—
—
trazodone; oral
N06AX05 [21604734]
N06AX05 [21604734]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
6
149
1489
Geriatric Medicine
38 [38004478]
38 [38004478]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
Tooth X-ray additional picture
EB1CA [2001301909]
EB1CA [2001301909]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
0
7
176
1751
—
—
—
—
0
14
149
1481
pseudoephedrine, combinations; oral
R01BA52 [21603213]
R01BA52 [21603213]
5.8e-01
5.0e-01
—
—
—
6.2e-01
4.9e-01
cases:19.32%
controls:11.83%
cases:6.82%
controls:4.27%
—
—
—
—
—
—
cases:7.06%
controls:3.92%
cases:19.46%
controls:12.84%
34
208
142
1550
12
75
164
1683
—
—
—
12
67
158
1644
29
192
120
1303
anastrozole; oral
L02BG03 [21603841]
L02BG03 [21603841]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
Contusion of other and unspecified parts of lower leg
S80.1 [45550389]
S80.1 [45550389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
—
Parvovirus B19 IgG Ab [Titer] in Serum
25630-5 [3009550]
25630-5 [3009550]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
149
1490
Constipation
D12 [2002000311]
D12 [2002000311]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
176
1751
—
—
—
—
—
—
Hypo-osmolality and hyponatraemia
E87.1 [45542779]
E87.1 [45542779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
7
149
1488
Insulin-like growth factor-I [Moles/volume] in Serum or Plasma
29775-4 [3014326]
29775-4 [3014326]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
6
149
1489
Depressive episode, unspecified
F32.9 [45571760]
F32.9 [45571760]
—
-1.0e+50
—
—
—
—
5.3e-01
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:4.03%
controls:2.41%
—
0
8
176
1750
—
—
—
—
6
36
143
1459
Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
32046-5 [3021584]
32046-5 [3021584]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
—
0
14
176
1744
—
—
—
—
—
Infiltrating duct carcinoma, NOS, of breast, NOS
8500/3-C50.9 [44505315]
8500/3-C50.9 [44505315]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
176
1752
—
—
—
—
—
—
Varicose veins of lower extremities without ulcer or inflammation
I83.9 [45552859]
I83.9 [45552859]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
0
14
176
1744
0
6
176
1752
—
—
—
0
7
170
1704
—
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
8.3e-02
-9.5e-03
—
—
—
9.0e-02
3.7e-01
cases:18.75%
controls:17.52%
cases:7.39%
controls:7.45%
—
—
—
—
—
—
cases:8.82%
controls:8.12%
cases:25.50%
controls:19.20%
33
308
143
1450
13
131
163
1627
—
—
—
15
139
155
1572
38
287
111
1208
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
SFC01 [2001310369]
2.9e-01
—
—
—
—
-1.0e+50
5.1e-01
cases:5.11%
controls:3.87%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
cases:8.05%
controls:5.02%
9
68
167
1690
—
—
—
—
0
19
170
1692
12
75
137
1420
Local infiltration anesthesia
WX111 [2001310768]
WX111 [2001310768]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
176
1751
—
—
—
—
—
—
Laceration/cut
S18 [2002000983]
S18 [2002000983]
3.0e-01
—
—
—
—
—
4.0e-01
cases:7.95%
controls:6.03%
—
—
—
—
—
—
—
—
—
—
cases:8.05%
controls:5.55%
14
106
162
1652
—
—
—
—
—
12
83
137
1412
Recurrent depressive disorder, unspecified
F33.9 [45581458]
F33.9 [45581458]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
8
149
1487
nimesulide; oral
M01AX17 [21604007]
M01AX17 [21604007]
7.5e-01
—
—
—
—
-1.0e+50
—
cases:2.84%
controls:1.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
5
24
171
1734
—
—
—
—
0
9
170
1702
—
Follitropin [Units/volume] in Serum or Plasma by Immunoassay
83098-4 [42529215]
83098-4 [42529215]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
176
1752
—
—
—
—
—
—
Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot
56723-0 [40759842]
56723-0 [40759842]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
8
149
1487
Psychiatric/psychological examination
SPAT1243 [2001700344]
SPAT1243 [2001700344]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
5
176
1753
—
—
—
—
—
Endometriosis of pelvic peritoneum
N80.3 [45606506]
N80.3 [45606506]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
176
1750
—
—
—
—
—
—
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
7.4e-01
1.4e+00
—
—
—
1.4e+00
5.9e-01
cases:3.41%
controls:1.65%
cases:2.84%
controls:0.74%
—
—
—
—
—
—
cases:4.12%
controls:1.05%
cases:4.03%
controls:2.27%
6
29
170
1729
5
13
171
1745
—
—
—
7
18
163
1693
6
34
143
1461
Contusion of finger(s) without damage to nail
S60.0 [45535417]
S60.0 [45535417]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
6
176
1752
—
—
—
—
—
0
6
149
1489
Pulmonary Disease
29 [38004472]
29 [38004472]
6.5e-01
7.6e-01
—
—
—
9.3e-01
5.8e-01
cases:10.23%
controls:5.63%
cases:6.25%
controls:3.01%
—
—
—
—
—
—
cases:7.65%
controls:3.16%
cases:12.75%
controls:7.56%
18
99
158
1659
11
53
165
1705
—
—
—
13
54
157
1657
19
113
130
1382
Continuous subcutaneous glucose monitoring
BEF00 [2001300849]
BEF00 [2001300849]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
5
176
1753
—
—
—
—
—
0
8
149
1487
buspirone; oral
N05BE01 [21604601]
N05BE01 [21604601]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
176
1751
—
—
—
—
—
—
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
3.6e-01
5.7e-01
—
—
—
3.8e-01
2.3e-01
cases:7.39%
controls:5.29%
cases:4.55%
controls:2.62%
—
—
—
—
—
—
cases:4.12%
controls:2.86%
cases:7.38%
controls:5.95%
13
93
163
1665
8
46
168
1712
—
—
—
7
49
163
1662
11
89
138
1406
Rash and other nonspecific skin eruption
R21 [45553721]
R21 [45553721]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
7
149
1488
Oxygen saturation in Venous blood
2711-0 [3024928]
2711-0 [3024928]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
176
1752
—
—
—
—
—
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
66
42
24.46
81.24
1.5
1.4
20.02
238.28
e6/l
0.81
46
32
65
41
24.47
80.29
1.4
1.3
155.20
3.00
e6/l
4.80
45
28
52
9
80.95
47.50
1.4
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
47
5
126.78
45.36
1.4
1.2
—
—
—
0
0
29
5
68.81
25.89
1.2
1.0
—
—
—
0
0
33
16
25.02
23.63
1.4
1.1
—
—
—
0
0
30
16
22.30
20.82
1.4
1.1
—
—
—
0
0
25
8
36.05
19.87
1.4
1.1
2.57
1.66
mmol/l
—
25
8
27
15
20.97
18.46
1.3
1.0
—
—
—
0
0
24
10
27.51
17.87
1.3
1.2
—
—
—
0
0
24
21
13.03
13.79
1.3
1.1
—
—
—
0
0
17
7
26.65
12.73
1.3
1.0
91.91
—
%
—
11
0
24
53
5.08
10.60
1.3
1.1
—
5.47
—
0
11
16
10
17.43
10.57
1.6
1.7
—
—
—
0
0
18
16
12.37
10.32
1.3
1.1
556.83
666.60
e6/l
—
12
10
18
16
12.37
10.32
1.3
1.4
273.08
161.64
e6/l
1.41
12
11
16
11
15.84
10.21
1.1
1.3
—
—
—
0
0
16
14
12.43
9.27
1.7
2.3
—
—
—
0
0
43
165
3.12
8.76
1.6
1.7
—
—
—
0
0
17
19
9.77
8.76
1.1
1.4
—
—
—
0
0
52
223
2.89
8.70
2.6
2.8
5.34
3.08
e6/l
0.41
18
104
14
11
13.69
8.53
3.8
2.7
342.57
637.91
u/ml
0.63
14
11
45
186
2.90
8.00
2.1
1.9
28.79
29.44
s
0.44
45
181
130
905
2.64
7.65
10.2
9.9
4.05
4.02
e9/l
0.05
118
798
42
171
2.91
7.65
1.7
1.7
—
—
—
0
0
11
7
16.63
7.33
1.3
1.0
—
—
—
0
0
50
234
2.58
6.91
1.8
1.8
—
—
—
0
0
51
242
2.56
6.85
2.4
2.7
0.85
0.74
e6/l
0.13
17
123
13
15
9.25
6.68
1.3
1.3
0.92
0.70
e9/l
0.68
13
15
20
57
3.83
6.37
1.4
1.4
—
—
—
0
0
53
268
2.40
6.14
4.1
3.0
24.03
62.85
ng/l
0.88
32
170
11
11
10.57
6.12
1.9
2.6
—
—
—
0
0
22
73
3.30
5.60
1.4
1.6
—
—
—
0
0
82
517
2.09
5.42
4.4
3.1
—
—
—
0
0
27
104
2.88
5.36
1.9
1.6
—
—
—
0
0
5
0
+∞
5.23
1.4
0.0
—
—
—
0
0
69
415
2.09
5.10
4.1
2.8
0.13
0.44
e6/l
1.98
45
304
15
45
3.55
4.43
1.4
1.4
—
—
—
0
0
79
521
1.93
4.36
3.9
3.5
21.43
19.40
ng/l
0.17
43
312
13
30
4.59
4.22
1.2
1.3
—
—
—
0
0
13
30
4.59
4.22
1.2
1.3
—
—
—
0
0
129
1014
2.00
4.08
6.2
4.7
—
273.84
—
0
19
18
65
2.97
3.99
1.9
1.6
—
—
—
0
0
10
19
5.51
3.89
1.0
1.2
—
—
—
0
0
58
358
1.92
3.81
1.5
1.7
0.58
1.02
mg/l
1.20
46
273
25
113
2.41
3.62
1.6
1.2
86.39
124.67
u/ml
0.33
25
102
7
9
8.04
3.59
1.6
1.0
2312.43
1522.67
miu/ml
—
7
9
107
810
1.81
3.59
3.8
3.3
89.91
86.18
ug/l
0.12
102
771
16
59
2.88
3.42
3.6
11.1
1.52
1.48
%
0.07
16
54
6
8
7.71
3.08
1.3
1.3
12.83
17.00
u/l
—
6
8
93
696
1.71
3.07
2.6
2.6
77.08
76.09
nmol/l
0.11
84
642
11
32
3.60
2.95
1.9
2.7
1.00
2.18
index
—
5
17
12
38
3.31
2.91
3.0
2.3
116.57
126.45
g/l
—
7
29
93
708
1.66
2.79
8.5
7.6
1.21
1.21
mmol/l
0.16
85
608
11
37
3.10
2.54
1.6
1.9
44.36
40.51
nmol/l
0.12
11
37
54
365
1.69
2.51
3.9
3.8
1.02
1.02
kg/l
0.62
37
238
72
529
1.61
2.40
4.1
3.2
28.26
28.52
u/l
0.05
66
500
43
278
1.72
2.33
3.4
2.2
—
—
—
0
0
6
13
4.74
2.29
1.0
1.2
—
—
—
0
0
6
13
4.74
2.29
1.0
1.2
—
—
—
0
0
10
35
2.97
2.25
2.0
1.5
—
—
—
0
0
5
9
5.68
2.23
1.6
1.0
—
—
—
0
0
142
1242
1.72
2.19
4.7
4.7
14.46
14.61
pmol/l
0.32
135
1165
45
302
1.66
2.12
3.8
2.4
—
—
—
0
0
130
1120
1.61
2.04
3.5
3.2
51.00
42.42
u/l
0.45
125
1077
10
38
2.73
2.04
1.1
1.3
—
—
—
0
0
105
864
1.53
2.01
5.6
3.8
0.00
8.29
estimate
0.50
18
196
131
1134
1.60
1.98
4.0
3.7
—
—
—
0
0
24
137
1.87
1.95
3.6
11.5
12.43
12.30
kpa
0.06
24
130
24
137
1.87
1.95
3.6
11.5
4.89
5.12
kpa
0.66
24
130
14
65
2.25
1.94
3.9
17.3
16.59
15.76
%
0.57
14
60
65
487
1.53
1.91
5.0
3.1
0.00
0.01
estimate
0.50
16
158
103
854
1.49
1.84
5.5
3.7
0.00
0.00
estimate
-0.00
19
191
164
1518
2.09
1.83
24.5
14.3
16.24
20.69
mg/l
1.84
144
1236
27
165
1.75
1.78
4.3
2.0
—
—
—
0
0
5
13
3.92
1.72
1.6
1.2
—
—
—
0
0
104
872
1.47
1.70
5.6
3.8
0.00
0.00
estimate
-0.00
18
184
146
1314
1.63
1.70
28.3
17.6
13.42
13.52
%
0.51
146
1300
28
178
1.68
1.61
2.6
2.7
6.57
5.95
umol/l
0.15
23
150
88
721
1.44
1.59
3.1
2.9
—
—
estimate
—
0
0
10
44
2.35
1.58
1.3
1.4
—
—
—
0
0
10
44
2.35
1.58
1.4
1.3
—
—
—
0
0
64
499
1.44
1.49
3.4
3.2
2.33
2.35
mmol/l
0.57
59
461
9
38
2.44
1.48
1.1
1.4
—
—
—
0
0
5
16
3.18
1.45
1.4
1.3
—
—
—
0
0
14
75
1.94
1.39
1.1
1.3
—
—
—
0
0
15
83
1.88
1.36
5.5
7.0
24.96
25.04
mmol/l
0.03
15
83
53
408
1.43
1.31
1.8
1.7
—
—
—
0
0
5
18
2.83
1.29
1.0
1.3
—
—
—
0
0
154
1431
1.59
1.25
6.1
5.6
1.76
1.83
mu/l
0.36
147
1348
10
49
2.10
1.24
2.9
2.0
—
—
—
0
0
24
159
1.59
1.20
1.8
2.9
0.81
0.74
ug/l
0.16
13
99
6
26
2.35
1.19
1.2
1.7
—
—
—
0
0
77
642
1.35
1.16
5.8
3.6
0.00
0.02
estimate
0.68
17
164
5
20
2.54
1.16
1.0
1.6
—
—
—
0
0
5
20
2.54
1.16
1.0
1.6
—
—
—
0
0
5
20
2.54
1.16
1.2
1.6
—
—
—
0
0
8
40
2.05
1.13
1.3
2.3
201.00
193.63
%
—
8
40
154
1439
1.54
1.12
4.7
4.4
5.67
5.77
mmol/l
0.62
145
1349
5
21
2.42
1.10
1.2
1.6
—
—
—
0
0
5
21
2.42
1.10
1.2
1.6
—
—
—
0
0
5
21
2.42
1.10
1.0
1.6
—
—
—
0
0
15
90
1.73
1.08
1.1
1.0
—
—
—
0
0
159
1499
1.60
1.07
25.6
15.4
3.92
3.94
mmol/l
0.64
159
1466
9
45
2.05
1.06
1.2
1.6
—
—
—
0
0
54
431
1.36
1.06
1.4
1.3
0.63
1.24
u/ml
1.09
16
139
9
50
1.84
0.98
1.2
1.1
—
—
—
0
0
9
50
1.84
0.98
1.2
1.1
—
—
—
0
0
7
36
1.98
0.98
1.3
1.3
—
—
—
0
0
150
1404
1.45
0.97
3.9
3.8
1.21
1.24
mmol/l
0.19
139
1309
46
368
1.34
0.89
2.7
3.1
1480.59
1118.88
ng/l
0.30
40
306
166
1592
1.69
0.89
16.7
11.1
25.94
25.19
u/l
0.32
166
1561
28
206
1.43
0.88
5.3
2.1
—
—
—
0
0
75
645
1.28
0.85
2.4
2.0
97.59
97.72
pmol/l
0.01
39
324
27
199
1.42
0.85
1.7
1.9
1.44
1.36
%
0.19
22
175
28
208
1.41
0.84
2.9
4.1
28.71
22.56
%
0.92
12
94
6
32
1.90
0.82
1.0
1.1
—
1.85
—
0
9
44
355
1.32
0.80
2.4
2.3
—
—
—
0
0
0
24
0.00
0.80
0.0
1.2
—
91.20
—
0
5
48
393
1.30
0.79
5.3
4.1
16.17
10.47
mg/mmol
0.27
25
240
152
1440
1.39
0.78
20.7
13.1
87.67
87.43
ml/min/173m2
0.05
145
1330
165
1588
1.58
0.75
27.8
17.1
74.73
72.31
umol/l
0.45
165
1572
5
24
2.11
0.75
1.4
1.7
—
—
—
0
0
19
134
1.47
0.75
4.1
3.5
—
—
—
0
0
27
205
1.37
0.73
4.6
2.5
26.64
23.51
%
0.58
27
192
5
26
1.95
0.71
1.2
1.5
—
—
—
0
0
29
225
1.35
0.69
4.3
2.4
2.28
2.39
g/l
0.51
29
206
45
373
1.28
0.67
1.5
1.5
—
—
—
0
0
5
28
1.81
0.66
12.4
2.9
14.74
7.69
pmol/l
—
5
28
7
44
1.61
0.66
1.1
1.1
—
0.91
—
0
7
5
29
1.74
0.64
1.4
1.7
—
—
—
0
0
11
71
1.59
0.63
6.5
2.9
23.54
24.61
mmol/l
0.74
11
71
23
175
1.36
0.62
13.7
7.0
1.08
1.06
mmol/l
0.14
23
156
18
131
1.42
0.62
5.4
4.1
18.73
59.93
ug/l
0.34
12
105
6
36
1.69
0.57
2.0
2.5
—
—
—
0
0
6
37
1.64
0.56
1.2
1.4
—
—
—
0
0
17
125
1.40
0.56
1.5
1.3
—
—
—
0
0
6
38
1.60
0.55
1.0
2.2
—
—
—
0
0
50
433
1.22
0.51
1.7
1.6
22.80
22.09
nmol/l
0.17
39
367
155
1495
1.30
0.49
4.7
4.6
4.65
4.71
mmol/l
0.33
148
1415
15
111
1.38
0.48
4.5
2.4
18.63
59.85
u/ml
1.12
15
105
11
77
1.46
0.47
1.2
1.6
—
—
—
0
0
22
176
1.29
0.44
4.5
6.8
106.32
104.53
mmol/l
1.49
22
176
11
78
1.44
0.44
5.0
12.1
24.65
24.39
mmol/l
0.13
11
73
13
171
0.74
0.42
3.4
4.3
30.00
31.89
%
—
7
113
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
12
88
1.39
0.41
1.3
1.5
89.43
322.21
miu/ml
—
7
44
11
148
0.73
0.40
9.6
6.2
—
—
—
0
0
20
161
1.27
0.39
1.2
1.3
21.83
121.40
u/ml
—
6
64
154
1493
1.24
0.39
4.6
4.5
1.48
1.49
mmol/l
0.11
146
1407
14
107
1.33
0.38
4.6
2.9
63.44
69.09
ml/min/173m2
—
9
45
38
330
1.19
0.38
1.3
1.4
4.11
10.88
u/ml
0.95
13
128
31
264
1.21
0.38
3.3
2.4
2.41
2.43
mmol/l
0.60
26
236
155
1508
1.22
0.34
5.3
5.0
2.66
2.79
mmol/l
1.06
148
1422
10
76
1.33
0.29
1.7
1.6
—
—
—
0
0
8
62
1.30
0.28
1.8
1.3
—
—
—
0
0
5
72
0.69
0.26
1.6
1.4
—
—
—
0
0
9
77
1.18
0.24
2.9
11.4
0.60
0.71
%
—
9
77
0
11
0.00
0.21
0.0
1.3
—
106.31
—
0
11
41
376
1.12
0.21
1.9
2.8
339.28
326.00
umol/l
0.39
36
336
44
473
0.91
0.18
6.7
3.9
0.00
0.01
estimate
0.50
17
181
5
68
0.73
0.17
1.0
1.1
1.51
1.60
g/l
—
5
68
5
69
0.72
0.17
1.0
1.1
0.87
0.84
g/l
—
5
69
18
158
1.16
0.17
1.8
1.8
3.33
3.46
mmol/l
0.21
12
115
9
80
1.13
0.15
2.9
10.7
1.11
1.40
%
—
9
80
13
113
1.16
0.13
2.7
2.6
5403.49
4008.96
u/l
—
7
45
168
1663
1.20
0.13
34.1
21.8
133.89
135.00
g/l
0.52
168
1650
168
1661
1.22
0.13
34.0
22.0
40.11
40.48
%
0.66
168
1646
168
1660
1.24
0.13
33.9
21.6
90.73
90.68
fl
0.05
168
1647
23
210
1.11
0.13
2.2
1.9
3.11
3.32
ratio
0.39
17
164
38
358
1.08
0.11
1.4
1.3
10.47
26.23
iu/ml
2.69
15
118
6
73
0.82
0.08
4.7
2.6
1.23
1.37
%
—
6
73
67
654
1.04
0.06
1.8
1.9
1.31
1.37
mmol/l
0.34
57
563
10
101
0.99
0.00
1.2
1.3
—
—
—
0
0
5
54
0.92
-0.00
2.0
1.5
61.10
50.81
ug/l
—
5
54
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
7
76
0.92
-0.00
1.3
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
5
53
0.94
-0.00
2.6
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
56.80
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
55
0.91
-0.00
1.0
1.4
—
—
—
0
0
6
68
0.88
-0.00
2.2
1.9
—
—
—
0
0
8
87
0.92
-0.00
1.5
1.9
5.72
3.05
ug/l
—
8
76
0
5
0.00
-0.00
0.0
3.4
—
129.00
—
0
5
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
6
61
0.98
-0.00
1.0
1.4
—
7.27
—
0
17
0
8
0.00
-0.00
0.0
1.4
—
194.88
—
0
8
0
9
0.00
-0.00
0.0
2.8
—
1.00
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint G6_MENINGVIR and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have G6_MENINGVIR.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: G6_MENINGVIR – Meningitis, viral
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data